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Executive Summary  
The Human Brain Project (HBP) is one of the Future and Emerging Technology Flagship 
initiatives, which are funded by the European Commission and promote ambitious and 
science-driven research initiatives. The HBP is a 10-year project in medicine, neuroscience 
and computing that brings together scientists and institutions from 20 nations across 
Europe.  
As part of this, the builders of the HBP Medical Informatics Platform (MIP) are working to 
identify the biological basis of brain diseases, with the long-term goal of informing the 
development of new treatments for neurodegenerative and psychiatric disorders. 
Developers of the HBP MIP are federating medical data from European hospitals, and 
deploying statistical clustering strategies to identify the brain signatures of these 
disorders.  
This report by the HBP Foresight Lab at King’s College London (Work Package 12.1) 
outlines the major societal and ethical challenges faced by MIP developers as they work to 
federate data and translate key health findings into clinical practice. It focuses on two key 
issues:  
 Data federation and privacy  
 Disease signatures and personalised medicine 
Data protection and data privacy present some major challenges for the federated 
organisation of the HBP Medical Informatics Platform, which our Foresight research 
suggests will be key to the future of the Project. We identify three such challenges that 
are interwoven in the multi-layered architecture of the MIP: legality, trustworthiness, and 
privacy. Some of these challenges may be addressed by measures for technology 
management; others may be addressed via community-building activities around the MIP. 
These activities could involve clinicians, the pharmaceutical industry and other 
professional stakeholders, as well as patient groups and the general public.  
Based on our research and our discussions with MIP developers, we recommend the 
following: 
1) Regular and systematic work on scenarios for misuse.  
2) An Information Security Architecture Partnering project within the MIP, to be 
established before the end of the Ramp-Up Phase, which would preferably be extended 
to the whole HBP, if such provision is not already in place. 
3) A Privacy Impact Assessment. 
4) Evaluation of consent requirements for different functions of the MIP, with a focus on 
informed consent wherever appropriate. 
5) Consideration of special issues that may arise from the use of data acquired from 
outside the EU. 
6) Protocols for engaging patient, patient support and stakeholder groups in respect of 
the different functions of the MIP. 
7) A Public Engagement and Research Dissemination Plan. 
8) A Data Governance Committee for the MIP with a broad membership including 
representatives of users and the public. 
9) A Research Audit structure that can identify, authorise and audit all users of the MIP. 
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Many challenges are raised by the interpretation of complex biological and clinical data to 
identify signatures that may be clinically useful in the diagnosis and treatment of mental 
disorders. Further challenges arise if such signatures are used to identify predispositions or 
susceptibilities to disorders. These challenges include: recognition and interpretation of 
statistical clusters within data; identification of when a particular biological signature is an 
indicator for a disease; translation of findings into protocols and guidelines for clinical 
practice; ensuring appropriate use of disease signatures by clinicians and patients, and 
preparing the regulatory and governance infrastructure for what is often termed 
‘personalised’ or ‘precision’ medicine. Many of these can only be addressed adequately by 
strong consultation and engagement with affected communities.  
On the basis of our Foresight work, we make the following recommendations to ensure that 
an effective partnership is created with patients, clinicians and other potential users of 
disease signatures: 
1) Include patients and clinicians in a research advisory capacity.  
2) Address implications for clinical practice, in particular by engaging clinicians in the 
assessment and verification of disease signatures and their utility in clinical 
applications. 
3) Address implications of disease signatures for clinical ethics. 
4) Reflect on the use of brain signatures in the identification of pre-clinical disease 
susceptibilities. 
5) Ensure awareness that differences in brain structure or function do not equal brain 
disease. 
6) Develop effective communication strategies to explain the potential clinical and 
research uses of brain signatures to the public at large and other audiences. 
7) Link with other research communities and relevant regulators to develop appropriate 
pathways for translation of research to clinical applications. 
8) Consider the wider implications of moving to a brain-based understanding of disorders 
9) Consider the implications for public trust and support of the HBP, of the future 
intended commercialisation of the findings to generate employment and wealth 
creation. 
These recommendations have arisen from foresight work with multiple sources, including: 
reviews of relevant literature and reports from professional bodies; discussions with 
stakeholders in formal and informal settings; webinars and seminars organised in 
collaboration with our partners in the Danish Board of Technology; and productive 
discussions with the directors and researchers of the MIP itself. Whereas we have already 
incorporated some of our recommendations into the developing MIP, some will require 
action by others as the work of the Human Brain Project progresses. These collaborations 
embody and enact the principles of Responsible Research and Innovation, and together aim 
to ensure that the work of the HBP is directed most fruitfully to meet the major challenges 
that psychiatric and neurological disorders pose to individuals, families, communities and 
societies.  
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1. Introduction 
1.1 What is the HBP? 
Understanding the human brain is one of the greatest scientific challenges in the 21st 
century. The Human Brain Project is based on the consideration that, by progressing in our 
research, we will be able to gain insights into what makes us human, to develop new 
treatments for brain disease and to progress in building revolutionary new computing 
technologies. And it argues that developments in Information and Communication 
Technology, for the first time, bring these goals within sight.1 
The HBP is a 10-year project co-funded by the European Commission2. The Project, which 
will have a total budget of over EUR 1 billion, is European-led and has a strong element of 
international cooperation. It has grown since its initial proposal and currently consists of a 
Consortium of over 100 partner universities and companies, covering more than 20 
countries in Europe and beyond. When it was launched in 2013 as one of the two Future 
and Emerging Technologies (FET) initiatives, 3  the European Commission welcomed the 
Human Brain Project as: 
“The world's largest experimental facility for developing the most detailed model of 
the brain, for studying how the human brain works and ultimately to develop 
personalised treatment of neurological and related diseases. This research lays the 
scientific and technical foundations for medical progress that has the potential to 
improve the quality of life for millions of Europeans.”  
Initial funding for the HBP was given for a 30-month Ramp-Up Phase, with further 
negotiations envisaged for the funding of the remaining seven and a half years of the 
Project. 
One of the major obstacles to understanding the human brain is the fragmentation of brain 
research and the data it produces. The HBP intends to gather international knowledge and 
advances in emerging information and communication technologies (ICTs) in order to 
integrate this data in a unified picture of the brain as a single multi-level system. The 
ultimate goal is to integrate existing knowledge in massive databases and in computer 
models of the brain. 
The HBP has three main “Flagship Strategic Objectives”: 
Future Medicine: Develop an objective, biologically grounded map of neurological and 
psychiatric diseases based on multilevel clinical data; use the map to classify and diagnose 
brain diseases and to configure models of these diseases; use in silico experimentation to 
understand the causes of brain diseases and develop new drugs and other treatments; 
establish personalised medicine for neurology and psychiatry. 
Future Neuroscience: Achieve a unified, multi-level understanding of the human brain 
that integrates data and knowledge about the healthy and diseased brain across all levels 
of biological organisation, from genes to behaviour; establish in silico experimentation as a 
foundational methodology for understanding the brain. 
Future Computing: Develop novel neuromorphic and neurorobotic technologies based on 
the brain's circuitry and computing principles; develop supercomputing technologies for 
brain simulation, robot and autonomous systems control and other data intensive 
applications.  
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1.2  The Research: King’s College London and the Foresight Lab  
From the initial conception of the Project, it became clear that many social and ethical 
issues would arise from the research. This is why an “Ethics and Society Programme” was 
included as an integral part of the Project. The aims of this programme are: to explore the 
Project's social, ethical and philosophical dimensions; to promote engagement with 
decision-makers and the general public; and, more generally, to foster responsible 
research and innovation by raising social and ethical awareness among Project 
participants.  
The Department of Social Science, Health and Medicine at King’s College London is part of 
this programme. We identify and evaluate the potential impact of the new knowledge and 
technologies produced by the HBP, in terms of benefits to European citizens, European 
industry and European society. To fulfil this aim, we established the King’s Foresight 
Laboratory. 
The Foresight Lab conducts systematic foresight exercises to identify and evaluate these 
impacts. We do this by adapting established foresight methods already in use in different 
areas of medicine and ICT, including modelling, horizon scanning and scenario planning. 
These methods involve recurring consultations with researchers, potential industrial and 
professional users of new technologies, civil society groups, regulators and other 
stakeholders. In particular, we have developed a set of scenarios, based on consultation 
with researchers, potential users of new technologies, civil society groups, regulators and 
other stakeholders, which will serve as frameworks and stimuli for evaluating the possible 
consequences of the HBP on different areas of society. 
1.3 Why Responsible Research and Innovation (RRI)? 
The demand for responsible research and innovation 4  has become widespread among 
research and development funding agencies across Europe. At its simplest, RRI is linked to 
the growing belief among policy-makers that funded research should address grand societal 
challenges. RRI thus aims to shape the research and development trajectory of emerging 
technologies, to ensure that they remain aligned with the values, needs and priorities of 
society at large. This requires everyone to consider the potential risks of their work and 
how these could be identified and mitigated, as well as the short, medium and longer-term 
societal consequences of their work. An RRI approach also encourages citizens to be aware 
of the day-to-day process by which research is done, and of decisions that may have 
unforeseen consequences. If key aspects of our collective future are born in the 
laboratory, then from the perspective of RRI, citizens should pay attention to what is 
happening there. 
“Responsible Research and Innovation (RRI) is the on-going process of aligning 
research and innovation to the values, needs and expectations of society.”  
Source: Rome Declaration on Responsible Research and Innovation in Europe, 
October 2015 
Of course, there are many difficulties with such aspirations. In many cases, it is only well 
after the introduction of any particular technology that there is a full understanding of its 
social, economic, environmental and health effects. This often comes only after these 
technologies have established themselves within the interlocking technical systems and 
infrastructure of society, i.e., when it may be difficult or expensive to remove or change 
them.5  
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In part, the demand for RRI in emerging technologies arises from the view that broadening 
the pool of decision-makers involved in introducing a new technology/health 
practice/medicine to include those directly affected by the technologies (lay input) might 
lead to better anticipation of potential adverse effects. In addition, RRI techniques may 
improve scientific researchers’ capacity to consider such consequences early in the 
development pathway, allowing them to make better-informed judgments. Likewise, RRI is 
associated with improving the capacity of the public to understand contemporary 
developments in science and technology, so that they are better able to participate in 
research governance. Lastly, increasing the number and diversity of persons contributing 
to technology decision-making may result in better design outcomes, creating more 
equitable technology that meets the needs of a greater diversity of people. 
RRI approaches encourage reflection among researchers, funders, specific stakeholder 
groups and citizens more generally, and feed that reflection back into the development 
pathway to shape research in the direction of public benefit. One UK-based science and 
policy funding body has helpfully characterised the RRI approach in terms of four 
dynamically interacting phases: Anticipation, Reflection, Engagement and Action (AREA):6  
 Anticipation: Describing and analysing the impacts, intended or otherwise, (e.g., 
economic, social, environmental) that might arise. Not to predict but to explore both 
anticipated and unanticipated impacts and implications. 
 Reflection: Reflecting on purposes, motivations and potential implications of the 
research, and the associated uncertainties, areas of ignorance, assumptions, framings, 
questions, dilemmas and social transformations these may bring. 
 Engagement: Opening up such visions, impacts and questioning to broader deliberation, 
dialogue, engagement and debate in an inclusive way. 
 Action: Using all of the above to influence the trajectory of the research and 
innovation process itself. 
The phases are not distinct in timing, but necessarily integrated across the whole pathway 
of research, development and (where appropriate) application or commercialisation. They 
are also intended to be capacity building for all members of the community. Anticipation 
occurs by engaging researchers with stakeholders and experts to think reflectively about 
the research system and their position within it. Possible outcomes become apparent when 
people from different parts of the research system interact. For example, patient groups 
may be aware of issues from the perspective of the patient that a researcher not involved 
in clinical work, or even a clinician, might not have realised. Patients, by hearing what 
researchers are planning, have their first opportunity to reflect upon the proposals and 
give feedback. In these cross engagements, the capacity to act by modulating the priorities 
of research or the design of intended health technologies is developed.  
While RRI may increase reflexivity among individual researchers, it does not focus only on 
the individual. RRI does not require individuals to anticipate research outcomes from their 
single vantage point, reflect upon these and engage the public, and then take action to 
restructure the research system. Enhancing the capacity of researchers is, in part, a side 
effect of bringing together actors from different parts of the research process, including 
bench scientists, stakeholders and members of the public, to develop the collective 
capacity to shape research strategy and system in a way that is informed by the dialogue 
between all parties. There is no guarantee that all parties will agree or that consensus will 
be the outcome of such a process. However, innovation choices (even the choice not to go 
forward with a proposed innovation) can in principle be better informed, and their likely 
social benefits enhanced, through the dialogue created by an RRI process.  
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Developing an RRI process that successfully embodies these principles is difficult. It relies 
on the good faith of participants, requires adequate resources, and must be carefully 
adapted to the particular circumstances of the research situation and relevant 
stakeholders. Developing and testing successful RRI practices is part of the greater 
research agenda of the Human Brain Project. 
1.4 What is Foresight? 
Foresight is the “practice of making ‘forward looks,’ of anticipating change, or making 
studies of future possibilities.” 7  Foresight differs from forecasting, the most common 
approach to the future used by engineers. Foresight considers multiple possible futures, 
whereas forecasting is an attempt (often using numerical calculation) to predict the single 
most likely future.  
“…Scenarios - i.e. many futures - and forecasting – one future – have different 
ontological and epistemological underpinnings. …In forecasting, the emphasis is on 
what is knowable in advance from evidence of the past. Uncertainty is treated as a 
‘lack of knowledge’. In periods characterised by rapid and stable growth, forecasting 
has proved to be a reliable approach to predicting the future. In situations 
characterised by complexity, turbulence and ambiguity, over-reliance on forecasting 
can be a fatal error.” 8 
A forecasting approach might describe uncertainty as ignorance or lack of knowledge, 
might expect or consider only one future, and might deal only with explicit worldviews. A 
foresight approach, however, sees uncertainty as intrinsic. There are many possible 
futures, and actions in the present (and indeed decisions taken at any point along the 
research and development pathway, as they interact with a host of external, contingent or 
loosely connected events) will shape which futures come into existence. 
Foresight also recognises that underlying values and knowledge influence how we perceive 
our past and present. Foresight aims to consider how such values may influence our 
present, past, and future. This is particularly important in multiple stakeholder 
communities, where values may vary within the collective of groups that must consider 
possible futures. Foresight is often participatory, involving many constituencies and not 
just experts and specialists. The additional or alternate insight from differing 
constituencies is made possible by a foresight approach that takes seriously the differing 
values within and between communities.  
To anticipate possible futures is to consider them now, in the present, and to prepare. 
Anticipatory approaches to foresight emphasise capacity building, either individually or 
collectively (societally or organisationally). Because we cannot be certain which of many 
possible futures we will experience, anticipatory foresight is a type of engagement with 
communities or individuals that helps them build, or begin to consider, the types of 
capacity that they might require to be successful in differing future scenarios.9 
To be useful, foresight must be grounded in empirical research. Foresight is different from 
speculative ethics, where many of the situations considered (regardless of the intellectual 
value of the considerations in themselves) are often implausible or very far in the future, 
making their relevance low. Science fiction approaches do not serve the interest of 
effective science policy development. 
Foresight is often commissioned as part of policy work. Foresight approaches have been 
used in areas as diverse as addiction and drugs, and photovoltaics. 10  The foresight 
timeframe suitable for policy work is usually quite close (in our case 5-15 years). Over 
longer timeframes, it becomes increasingly hard to provide empirical backing to justify the 
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range, amount and direction of variability that the future may have; the work becomes 
more speculative, and hence has less value. 
Foresight uses a range of methods. 11  These include Scenario Planning, Delphi studies, 
Horizon/Environmental scanning, back casting, judgements made from the previous 
historical range of plausible outcomes, and sometimes road mapping or (product) life-cycle 
analysis, particularly anticipatory life-cycle analysis.  
Foresight is only one element within RRI; it should be linked to variety of other aspects of 
technology assessment. As such, foresight must be integrated with public engagement, 
reflection, as well as the actions of researchers, stakeholders, and publics in responding to 
anticipations of some particular future.  
1.5 Future Medicine in the HBP and the Focus of this Report  
The Human Brain Project has chosen Future Medicine as one of its three main research 
areas, the others being Future Neuroscience and Future Computing. Future Medicine is the 
focus of our first report. In the HBP, researchers in Future Medicine are developing an 
objective, biologically grounded map of neurological and psychiatric diseases based on 
multi-level clinical data. They are using this map to classify and diagnose brain diseases, 
and to configure models of these diseases. They are also using in silico experimentation to 
understand the causes of brain diseases and develop new drugs and other treatments, and 
they are establishing personalised medicine approaches for neurology and psychiatry.  
This work takes, as its primary data, clinical and hospital records of patients treated for 
psychiatric and neurodegenerative diseases across Europe and other regions. The 
underpinning hypothesis is that it is possible to aggregate and ‘mine’ these data to derive 
objective biological signatures of brain disease. These will be used for diagnosis, more 
accurate prognosis and to open up new types of drug discovery pathway for the 
development of new medicines. The aim is to identify distinctive patterns of data from 
brain scans, genetic tests and other indicators that will distinguish individual disorders 
more accurately than current techniques, which are largely based on classification by 
observable symptoms rather than underlying pathology. Such ‘disease signatures’ could 
enable more accurate prognosis and diagnosis of individual patients in the future, based on 
a better understanding of their specific neuropathology, thus also enabling more accurate 
choice of the treatment that is thought to be most appropriate and effective for specific 
persons and their conditions. This is what is meant by ‘personalisation’ in this context. 
Furthermore, in the future, it is hoped that it might be possible to identify patients at risk 
on the basis of these disease signatures, before the disorder becomes manifest or at an 
early stage in its development. This should allow more opportunity to intervene to 
forestall or mitigate its consequences.  
We consider some of the key social, legal and ethical questions raised by this endeavour, 
with a focus on two areas: issues of data protection and data privacy that are raised by 
accessing and analysing patient records; as well as the nature and consequences of the 
search for brain-based ‘signatures’ of psychiatric and neurodegenerative diseases, and 
their use in personalised medicine. Our Foresight Lab will explore time horizons of up to 25 
years during and beyond the HBP’s Operational Phase; however, in the current Ramp-Up 
Phase, we have focussed on issues that may arise during the 10-year Project itself. 
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1.6 Aims and Methods of this Report 
We have explored some of the key social and ethical issues that are emerging, or have the 
potential to emerge, from the HBP’s strategic objectives concerning ‘Future Medicine.’ For 
this first report, we focus on a relatively short timescale. We consider the issues that could 
emerge over the life of the Project, and that have fairly short-term implications for 
strategic decisions concerning the management of that part of the HBP’s work. 
This primarily concerns the work of the HBP Medical Informatics Platform. In particular, it 
concerns the MIP’s aim to ‘federate’ clinical data on patients with psychiatric and 
neurological diseases from hospitals and research sites in Europe and elsewhere, and to 
‘mine’ these data in the hope of identifying ‘brain signatures’ of disorders which could 
inform ‘personalised medicine.’ These twin aspects - data federation and brain signatures 
of disorder or disease - are the two foci of this report. 
We have used a mixed method loosely built around scenario or vignette construction. The 
scenarios were developed though detailed engagement with the technical and social 
literature and discussions with experts. This process was further supported by two 
webinars with external stakeholders and HBP researchers, organised jointly with our 
colleagues at the Danish Board of Technology (DBT), to discuss key future medicine issues 
arising from data federation, data mining, the search for brain signatures, and the 
development of personalised medicine. Based on these diverse interactions, we developed 
a set of brief narratives concerning different plausible aspects of HBP futures. These were 
used to spark conversation in another seminar that brought together researchers from the 
MIP and various stakeholders and experts.  
Our scenarios were used in a seminar organised by our colleagues at the DBT on data 
federation and personalised disease signatures.12 The collaborative process was designed 
to collect data for this future medicine report, to facilitate interaction and reflexive 
debate between different levels of the research community, and to identify key issues for 
further discussion between researcher and stakeholder communities.  
We identified number of key issues based on this work that are relevant to the strategic 
development of this part of the HBP. We formulated a number of recommendations, which 
were then fed back to the senior management of the Human Brain Project for deliberation 
and potential action.  
It is not the Foresight Lab’s role to act as the social and ethical regulator of the HBP, nor 
to require or mandate particular actions. This would be inconsistent with the dialogic and 
capacity-building ethos of responsible research and innovation. In consonance with the 
principles of RRI, the role of our reports is to enhance capacity among the HBP managers 
and researchers at all levels, across the HBP’s widely dispersed laboratories and research 
projects, so that they may make more informed, socially and ethically aware and 
responsible decisions regarding short-, medium- and long-term research planning. 
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2. Future Medicine: Background and Challenges 
2.1 The Work of the Medical Informatics Platform of the HBP 
The Human Brain Project (HBP) is, in part, a response to the fragmentation of brain 
research and the data it produces. To accelerate the pace of brain research, the HBP aims 
to provide an integrated system of ICT Platforms offering services to neuroscientists, 
clinical researchers and technology developers. The Medical Informatics Platform (MIP), 
which is being developed in Subproject 8 (SP8), is one of six ICT Platforms being set up in 
the Ramp-Up Phase of the HBP. The MIP was conceived, in part, to address the problem 
that neurological and psychiatric diagnosis, which currently relies largely on symptomatic 
classification, is beset by problems of reliability and validity, and also by the very 
considerable co-morbidity between different diseases, as currently classified.13  
“The way we understand and treat disease is changing rapidly. The list of 
conditions for which there is no satisfactory treatment is increasing and, even 
when treatments are available, many patients either do not respond or 
experience unacceptable side effects… It is clear that we must move away 
from a one-size-fits-all approach and towards healthcare that is tailored to 
the needs and characteristics of the individual. Personalised medicine is a new 
approach to classifying, understanding, treating and preventing disease based 
on data and information on individual biological and environmental 
differences. It seeks to integrate data on the entire dynamic biological 
makeup of each individual as well as the environmental and lifestyle factors 
that interface with this makeup to generate a complex, individual phenotype. 
Using this information, models can be generated to identify the most 
appropriate healthcare choices, from treatment to prevention, in individual 
citizens.” 
Source: European Science Foundation (ESF) (2012) Personalised Medicine for 
the European Citizen – towards more precise medicine for the diagnosis, 
treatment and prevention of disease. Strasbourg: ESF. 
For many years, researchers in psychiatry and neurology have sought to identify the 
precise neurobiological mechanisms that many increasingly believe underpin, or ‘subserve’ 
the symptoms that patients exhibit in their everyday lives and in clinical settings. As far as 
psychiatric disorders are concerned, a well-funded diverse programme of research carried 
out by research groups in many countries has tried to discover ‘biomarkers’ - patterns of 
genetic data, brain imaging or other physiological measures - that would enable them to 
precisely diagnose the problem from which the specific patient was ailing, and to target 
therapies for an underlying neurobiological pathology.  
It was hoped that identifying such biomarkers would enable a diagnosis to be made at an 
early point, or even pre-symptomatically, to enable preventive medicine. This approach, 
often referred to as personalised, stratified or precision medicine, is not confined to 
psychiatry, but has been a more general aspiration among research funders and policy 
makers for the last decade. 14  However, in psychiatry, success has been negligible: 
advanced genetic studies have not been able to identify a single genetic variation that can 
be linked to a high probability of a specific psychiatric diagnosis. The same is true of 
research using brain scanning or other methods. It had been hoped that the two major 
international diagnostic systems in psychiatry – the International Classification of Disease 
(ICD) and the Diagnostic and Statistical Manual (DSM) – both of which have been in a 
process of revision – would be able to include some biomarkers to underpin their disease 
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classifications. However, despite much research and high aspirations, by the time the fifth 
edition of the DSM was published in 2013, not a single clinically validated biomarker was 
available for any psychiatric disease. 15  The same has been true of attempts to find 
clinically reliable biomarkers for the major neurodegenerative diseases, notably the 
dementias. Despite some promising results that are providing the basis for further 
research, clinically reliable and robust biomarkers that can be used to identify 
unequivocally the presence of a disease are lacking, and diagnosis continues to rely upon 
symptoms and psychological tests, rather than the precise identification of an underlying 
neuropathology.  
It is in this context that many have suggested an alternative approach. 16  They have 
suggested that a major problem with previous research is that research subjects have 
initially been classified on the basis of their evident symptoms (i.e., classified by the DSM 
or ICD as falling into one or other diagnostic category), after which research has attempted 
to find biomarkers for these symptomatically defined categories. But if the symptomatic 
categories are misleading – for example, if the category of schizophrenia includes patients 
who may appear symptomatically similar, but whose conditions arise from a whole variety 
of different underlying neurobiological causes – results will inevitably be confused. 
Perhaps, then, similar symptoms arising from diverse genetic or neurobiological pathways 
are conflated into a single diagnostic category. On the other hand, perhaps conditions that 
appear quite different symptomatically arise in fact from rather similar underlying brain 
anomalies. Indeed, a recent paper published by the Cross-disorder Group of Psychiatric 
Genomics Consortium suggests that from a genetic point of view there is only one 
psychiatric disorder but multiple manifestations.17  
To overcome such problems, many now suggest that one should abstain from any initial 
division of patients by symptomatic diagnosis. Instead, one should simply explore the 
genetic and other neurobiological data, to see if one can identify clusters of anomalies at 
this level – at the level of the genetics or the neurobiology itself. Then, one can see 
whether these might map symptoms in a new way at a second stage, subdividing some 
‘traditional’ diagnoses and grouping together others. One might then explore whether 
therapies targeted at these underlying neurobiological anomalies would be more effective 
than those that we already possess. 
For those who take this view, the possibilities for identifying such disease clusters lie in 
the analysis of large quantities of data. This is because large quantities of data from many 
patients are required to give the data analysis sufficient power to sift through all the 
different variables and find statistically significant correlations that can enable the 
identification of these clusters. To gather such data afresh would be a daunting and 
expensive undertaking, although there is already research seeking to do just that. However 
another approach is possible: to use the vast quantity of existing data - genetic, 
physiological and brain imaging data - that has been gathered from many patients and that 
often lies unexplored in their medical records in hospitals and clinics. Public research 
groups and pharmaceutical companies also gather such data in the course of research. If 
such data could be brought together and standardised through a common platform, and 
‘mined’ for correlations and clusters, it is hoped that patterns which are impossible to see 
in a few individual patients will become apparent – ‘brain signatures’ of psychiatric and 
neurological diseases and disorders.  
This is the context of the MIP’s work. The goal of the MIP is to allow researchers to identify 
the complex biological mechanisms that explain brain diseases. It aims to bring together -  
or federate - imaging, genetic and other clinical data that reside in individual hospital, 
research and clinical trials archives and databases. All this is to be done while 
guaranteeing protection for sensitive patient information. It is hoped that these resources 
will permit the identification and constant updating of unique biological signatures of brain 
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diseases. These will be used for diagnosis, more accurate prognosis and to open up new 
avenues of drug discovery for the development of new medicines.  
The MIP will provide the research community with tools for epidemiological exploration, 
interactive analysis of new models and methods for diagnosis and treatment, and 
identification of biological signatures of diseases using data mining algorithms. The 
services of the MIP will be accessible online via the HBP Unified Portal (UP), which will 
provide a single point of access to all the HBP ICT Platforms. The MIP hopes to provide 
end-to-end solutions ranging from processed data to advanced analytical tools. 
Researchers would then be able to investigate questions requiring data correlation, 
distribution and interaction in the context of disease processes and epidemiological 
factors. By using the analytical and predictive tools provided, creating new such tools, or 
developing data mining algorithms for the validation of new biological signatures of 
disease, researchers will be able to investigate the relationships between biological and 
demographic variables and clinical phenotypes. Simultaneously, as further data accrue and 
new hospitals and data generators are recruited, data mining tools will allow exploration 
of all the data, to detect recurrent patterns with the aim of identifying biological 
signatures of disease. It is hoped that such biological signatures of disease will generate a 
‘diseaseome’, by forming the basis for a new disease space that neuroscientists and 
clinicians can explore.18 
The MIP will integrate large volumes of clinical and research data for mining by tapping 
into public and research databases and hospital data, federated by novel data 
management and querying techniques. MIP developers are creating a complex 
technological platform to achieve this, and hope that their federation software and 
hardware will allow researchers to query and analyse a very large volume of data without 
moving them from local servers or compromising data privacy.  
Prior to the engagement with our Foresight work, the considered view of the leading 
researchers in the MIP was that the technical design of the federation architecture, as 
illustrated in Figure 1 below, was sufficient to ensure the complete anonymity of data 
subjects, and would meet both present and any future reforms of data protection law. 
Participating hospitals, clinics and other organisations would have the responsibility of 
maintaining and protecting data as required by their local Institutional Review Boards and 
institutional regulations, and all local and national laws. They would place data from their 
clinical records, stripped of directly identifying details (such as name, date of birth, 
address) into a local ‘data store mirror’ which would have no ‘feedback’ connection to the 
original data itself. The level of detail copied in the local mirror would be under the 
control of the local institutions themselves, and could thus vary from institution to 
institution. This depersonalisation would constitute the initial step in the anonymisation 
process. The hospital data managers would control the type and quantity of data they 
provide to the data store mirror, and would be able to alter these with fine-grained 
control, thanks to the development of novel configurable security mechanisms. The MIP 
would provide the hospital (at the hospital’s expense) with both the local data store mirror 
and a local node server, which would be able to interrogate the data mirror in response to 
a query coming through the Data Federation infrastructure. 
The key part of the anonymisation procedure would consist in two further steps in the 
anonymisation process, as only aggregate queries could be executed on the de-identified 
data with results going through a double round of aggregation, firstly at the level of the 
hospital local node server, then at the federation level. Nothing but these aggregated 
results would come out from the MIP into the outside world. A suitably accredited 
researcher could then file a query via the web portal; this would be broken into pieces and 
distributed to the hospitals which data mirror contains data relevant for answering; the 
local servers collect, aggregate and send the data back to the data federation layer for 





Report on future medicine_Website version Dissemination: PU  26-Jun-2015 Page 14 of 65 
 
consolidation and secondary aggregation, which is returned to the researcher’s terminal. 
There would be no way back from the de-identified and doubly aggregated query result to 
the individuals whose clinical data participated in the result to the query. 
 
Figure 1: The technical architecture of the Medical Informatics Platform 
2.2 Data Federation, Data Protection and Data Privacy 
The first major social and ethical issues that we consider in our report concern data 
protection and data privacy. While much potentially valuable medical information on 
psychiatric and neurodegenerative disorders remains unexamined and locked away in the 
clinical records of patients in hospitals across Europe and beyond, accessing, aggregating 
and interrogating these data presents a number of challenges. In most cases, these data 
are historical – that is to say they were collected in the past in the course of medical 
treatment or, in some cases, in the course of clinical trials for matters unrelated to the 
work of the HBP. 
Have patients given their consent to the use of these data for this kind of research? If not, 
what steps need to be followed to ensure consent, or are there any circumstances where 
the data can be used without requiring such consent, for instance if it is completely 
anonymised and aggregated? Can absolute privacy be assured, such that the obligations 
enshrined in data protection legislation in all the relevant jurisdictions can be met? Is 
there a conflict between the ethical principle that might insist that these data be used for 
the public interest, and the ethical principle that might insist that these data remain the 
property of the individual, and can only be used if that individual gives specific informed 
consent?  
Concerns about data protection have become highly salient in Europe (and elsewhere) 
recently, and these have major implications for data federation in the HBP. There are two 
linked issues here – legality (i.e., compliance with legal norms and provisions at EU level 
and at country level) and trustworthiness. As far as legality is concerned, in 2012, the 
European Commission proposed a comprehensive reform of the EU's 1995 data protection 
rules, partly because the legislation had been implemented differently in different 
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member states leading to fragmentation and additional bureaucracy, and partly because 
technological progress had changed the way that data was collected and accessed. The 
initial draft legislation required specific and explicit consent for the use and storage of 
personal data, but allowed various exemptions for medical and health-related research, 
enabling it to be processed for medical and epidemiological research, without specific 
consent from each individual, provided that the data was ‘pseudo-anonymised’, that is to 
say, the individual’s identity was masked to protect privacy, and provided that the 
research was subject to strong ethical and governance safeguards, for example as 
approved by a competent research ethics committee. However, in the wake of the 
revelations about the mining of electronic data by the US National Security Agency, the 
draft was amended by LIBE, the Civil Liberties, Justice and Home Affairs Committee of the 
Parliament, and the new draft legislation, currently being debated at the time of writing, 
prohibits the use of such personal medical data without specific consent by each ‘data 
subject’ for each particular use of the data.19 This amended draft is strongly contested by 
a large number of medical and scientific research organisations across Europe, on the 
grounds that it would seriously damage medical research.  
In the case of the HBP, such a modification of the legislation could make it exceptionally 
difficult to federate and mine data as proposed by the MIP, where broad consent for the 
research use of their data has not been obtained from the patients concerned, or from 
their families or guardians, if they were deceased or otherwise unable to provide such 
consent. While the MIP procedures described earlier aim to provide complete anonymity, 
and it is formally the case that fully anonymised data falls outside the remit of the Data 
Protection regulations, as we shall see, some argue that full and complete anonymisation 
is technically impossible, and hence may question the claims made for the anonymisation 
procedure adopted by the MIP.20 The question of the legality of the MIPs data federation 
technology, in the light of current and forthcoming legislation and regulation, provided 
one key theme in our foresight work on Future Medicine for this report. 
It should be pointed out that legality does not in itself ensure trustworthiness; public trust 
in research may require more than simply compliance with existing legislation. This 
recently became very evident in the controversy about the care.data programme in the UK 
(http://www.england.nhs.uk/ourwork/tsd/care-data/). This project differed from the 
MIP, because it proposed aggregation outside the firewall of participating data providers, 
whereas the MIP proposes that this happens inside the firewall. Nevertheless, it clearly 
illustrated that trustworthiness cannot be assured solely by technical means. The 
care.data proposal to allow personal data from general practitioners and hospitals to be 
aggregated in electronic form and mined for the purposes of medical research was mired 
in a storm of controversy. Although entirely legal under current UK legislation, there was a 
distinct lack of adequate consultation with the population whose data was to be shared for 
the purposes of research. There were also inadequate procedures for patients to 'opt out' 
of the programme; in fact, the default option was that patients were automatically 'opted 
in' for data sharing. A further concern among the many critics of the proposal was that, in 
certain unspecified circumstances, patient data would be made available to commercial 
entities. Even in a cultural environment of strong trust in the UK National Health Service, 
care.data failed to gain the trust of those whose data it would use, and implementation 
was postponed until new procedures could be put into place to secure that trust.  
2.3 The Problems of Diagnosis and the Search for Disease Signatures 
We consider the issue of biological signatures of disease. As we have said, previous 
research on ‘biomarkers’ of psychiatric or neurobiological disorders of current diagnostic 
categories – i.e., objectively measureable biological characteristics that can indicate the 
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presence and nature of a disease in a living individual – has proved remarkably 
unsuccessful. At present, despite many hopes and premature claims, there are no clinically 
validated biomarkers of any neurological or psychiatric disease that can be used in living 
patients to guide diagnosis, treatment or early intervention. 
Recently, a new approach has been advocated that avoids initial classification by current 
diagnostic categories, such as those used in the DSM or ICD. This approach involves 
gathering large quantities of biological data on patients (e.g., from brain scans and various 
tests) and then analysing these data to find clusters of these biological measurements that 
might help to re-classify patients, not on the basis of observable symptoms, but of 
underlying neuropathology. Clusters derived in this way will, in a second stage, be related 
back to symptomatology in order to assess whether an approach based on biology alone 
will provide better clinical specificity and sensitivity in determining effective treatment. 
This approach could enable researchers to investigate the relationship between biological 
variables and clinical phenotypes. The goal is to produce biologically based diagnostic 
categories and procedures to enable clinicians to identify the precise pathology that 
underpins the illness of each individual patient, to personalise treatment, and to 
eventually develop screening tests to identify and intervene on patients at risk before 
disease develops. 
This approach also faces social and ethical challenges. Most biomarkers are probabilistic 
rather than deterministic, and this raises dilemmas for treatment. For example, a 
probabilistic biomarker might indicate that an individual was in a population group that 
was unlikely to respond well to a particular and expensive treatment, and hence that 
treatment should not be made available to them. 21  Screening for biomarkers, with 
intervention on the basis of biomarkers, raises questions concerning potential false 
positives and false negatives, and the consequences for self-identity, stigma and social 
expectations. 22  In the case of neurodegenerative disease, issues also arise if pre-
symptomatic biomarkers identify a risk of a condition for which no effective treatment is 
available. Hence, the second focus of our research for this first report on Future Medicine 
examines the social and ethical dilemmas that are raised by the search for brain signatures 
in psychiatric and neurological diseases. 
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3. Data Federation and Privacy: Foresight 
3.1 Background Scenarios 
The first set of major social and ethical issues considered in our report relate to data 
protection and data privacy in the federated MIP architecture. Together, they present 
three main types of challenges to the research team developing the MIP, which we think 
are key to the future of the Project: legality, trustworthiness and privacy in relation to Big 
Data expectations. 
To explore these issues, the Foresight Lab developed three narrative and fictional short 
scenarios (vignettes) and sets of questions for a stakeholder seminar organised in 
collaboration with the Danish Board of Technology Foundation (DBT) in Copenhagen in 
October 2014. It is important to stress that the scenarios are not predictions of what will 
or might happen, or anticipations of likely problems or eventualities. As we discussed 
earlier, the scenarios were intended to illustrate and dramatise potential futures, 
incorporating external events and contingencies that could affect research and 
development, to provoke debate and discussion. The scenarios focussed on problematic or 
negative possibilities in order to provoke debate, not to suggest that these would in fact 
occur. Indeed, in these discussions, it became clear that some of the futures pictured in 
the scenarios were unlikely; that other contingencies not embodied in the scenarios were 
actually more probable; and that for some eventualities, measures of mitigation were 
already in place. 
The analysis, conclusions and recommendations in this report have been informed by these 
lively debates, and the constructive discussions that occurred in this seminar and in other 
interactions that were sparked off by this event. As intended by our Foresight work, these 
discussions have already fed into clarifications and some modifications of the procedures 
and processes adopted by the MIP. The webinars and workshops for this report were 
concluded by November 2014, and we present the current protocols of the MIP as of 
January 2015 in the Annex.  
3.1.1 Scenario 1: The Price of Success 
By 2024, the HBP Medical Informatics Platform has succeeded beyond expectations. 
The data federation protocol has been widely accepted by hospitals and large amounts 
of clinical data have been federated, without the need to obtain individual consent 
from ‘data subjects.’ Over the past few years, despite the significant human and 
material investment required, research hospitals as well as general hospitals across 
Europe have been flocking to enrol as collaborating institutions, to give their 
researchers and clinicians access to the wealth of resources offered by the Platform. 
However, wide adoption brings some sloppiness of procedures. 
This scenario considered the possibility that a widely implemented, successful MIP could 
lead to participating institutions and their ethical boards becoming hasty in their eagerness 
to deploy a local MIP server in their IT infrastructure. The scenario develops a possible 
consequence of such hastiness: that personal data could enter the public domain because 
of inadequate implementation of the de-identification procedures in the hospital 
concerned.23 What other implications could it have?24 What could be the consequences for 
the MIP? In particular, could the MIP be held co-responsible with the incriminated 
institutions for the breach of anonymity? What steps could be taken to minimise the risk of 
such occurrences?25 Is this a technical problem, or (as some suggest) is it that complete 
anonymity is impossible to guarantee? 
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3.1.2 Scenario 2: The Costs of Early Adoption 
By 2024, the HBP Medical Informatics Platform has achieved only partial success in 
getting European hospitals to collaborate. Only a few research hospitals are 
participating, and the MIP has entered into partnerships with other, non-European 
brain projects as sources of research data. 
This scenario was concerned with the possible implications that the failure to enrol a 
sufficient number of European public hospitals could have for the MIP and participating 
institutions. It develops a set of ethical and economic consequences that could impact 
hospitals that have joined the MIP. What changes in strategic choices could such a partial 
failure mean for the MIP roadmap? What could be the consequences for other actors of the 
wider MIP, including its sub-contractors? What steps could be taken to ensure that the 
‘early joiners’ do not get penalised by possible changes of strategy? And what might be the 
implications of the MIP, and the HBP, using data that comes from countries and regions 
whose ethical protocols are widely considered to be less robust? 
3.1.3 Scenario 3: The Citizen-Patient Alternative 
By 2024, the HBP Medical Informatics Platform has failed in its objective of enrolling 
hospitals to collaborate. Despite sophisticated anonymisation protocols, getting ethical 
approval for accessing existing patient data without their expressly informed consent 
has proven to be a fatal hurdle. Another major cause for the difficulties of the MIP’s 
partnering with hospitals was that the overall investment proved very costly, while the 
returns in terms of clinical benefits were dubious. 26  In the meantime, another 
consortium of neuroscientists has chosen a different strategy that is proving successful, 
but this strategy also has its downsides. 
This scenario considered the possibility that the MIP could fail at implementing its planned 
federated infrastructure of public hospital, in part because of the problems of consent.27 It 
explores the idea of an alternate distributed infrastructure, implemented with the 
collaboration of patients and patients support groups. How could such an alternative 
model develop? How could it interface with the general public health services and in 
particular the public hospitals? What would be its economics? Would it represent a 
preferable model to be adopted by the HBP? 
3.2 Emerging Challenges 
The challenges of legality, trustworthiness and privacy in relation to expectations 
concerning ‘Big Data’ were discussed at length in our webinars, seminars and workshops. 
They have also been much explored in the published literature, including in other reports 
from social and ethical enquiries. In this section, we distil the main challenges from these 
various sources, and then, in the next section, we make some recommendations for best 
practice that have emerged from our discussions and debates. Legality, trustworthiness 
and privacy are very much interwoven in the ethical and social issues raised by data 
federation, protection and privacy in the multi-layered architecture of the HBP Medical 
Informatics Platform. But distinguishing them, as we do here, brings to light different 
perspectives on these issues. 
3.2.1 Legality 
To have a chance at succeeding, the Project must conform to the law. Yet in the case of 
the MIP – a data federation platform with a multi-layered architecture, which may be 
deployed across diverse organisations in many different countries, each with their own 
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legal requirements – we are faced with a level of complexity that poses its own legal 
challenges.  
In the MIP’s federated architecture, participating local hospitals and other collaborating 
institutions would each house a local MIP server, which would only store a pre-processed, 
anonymised and partial mirror of the records database held by the institution, protected 
by a firewall. These data would never leave the local MIP server, which would be 
responsible for pre-processing and aggregating the data in response to queries coming 
through the MIP central federation server. Users of the MIP would interact with the central 
federation server via the web services offered by the HBP Unified Portal.  
This federated architecture raises two main legal challenges. The first is that of the 
protection of privacy under both EU Data Protection and Human Rights laws. The technical 
solution chosen by the MIP team consists of combining techniques of data de-identification 
and double aggregation in such a manner that the MIP would guarantee anonymity, while 
retaining enough meaningful information to present an interest for research through 
statistical power and data mining. This would allow the MIP to use historical data from 
hospitals’ patient records and, possibly, past clinical trials by pharmaceutical companies, 
without having to re-obtain specific consent from each individual. A widespread view of 
many information security experts and researchers at the Copenhagen seminar was that, 
from a technical perspective, complete anonymisation cannot be ensured. According to 
Opinion 05/2014 on Anonymisation Techniques of Article 29 Data Protection Working Party, 
adopted 10 April 2014,28 no existing technique can ensure full anonymity. The Opinion has 
analysed the robustness of each technique based on three criteria: 
1) Individual identification: Is it still possible to single out an individual? 
2) Linkability: Is it still possible to link different types of records relating to an 
individual or a group of individuals? 
3) Inference: Can information be inferred concerning an individual or a group of 
individuals? 
This last criterion opens the door to the possibility of targeted inference attacks, where 
dates (such as hospital admission/discharge, consultation) are particularly weak links. 
Experts in data security at the Copenhagen seminar thought that despite the extensive 
precautionary measures taken by the MIP team in designing the data anonymisation and 
aggregation process, malicious misuse of the Platform services could not be entirely ruled 
out. Many felt that the scenario presented in the first of our vignettes, which highlighted 
the possibility that with success could come sloppiness, and that de-anonymisation might 
lead to class action against hospitals participating in the MIP, was quite realistic. 
The k-anonymity technique retained for the anonymisation module of the MIP can prevent 
individual identification, but linkability and inference remain recognised risks. The 
motivation of a hacker to conduct inference attacks on a large medical database could be 
for instance to find the medical records of an important person, or the identities of a 
group of people affected by a specific condition, in order to blackmail them. Moreover, 
with our increasingly networked and complex information infrastructures, accidental 
blunders and security breaches are on the rise and cannot be discounted. 
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‘The Information Commissioner’s Office (ICO) has served a £180,000 penalty 
on the Ministry of Justice over serious failings in the way prisons in England 
and Wales have been handling people’s information. 
The penalty follows the loss of a back-up hard drive at HMP Erlestoke prison 
in Wiltshire in May 2013. The hard drive contained sensitive and confidential 
information about 2,935 prisoners, including details of links to organised 
crime, health information, history of drug misuse and material about victims 
and visitors. The device was not encrypted. 
The incident followed a similar case in October 2011, when the ICO was 
alerted to the loss of another unencrypted hard drive containing the details 
of 16,000 prisoners serving time at HMP High Down prison in Surrey. 
In response to the first incident, in May 2012 the prison service provided new 
hard drives to all of the 75 prisons across England and Wales still using back-
up hard drives in this way. These devices were able to encrypt the 
information stored on them. But the ICO’s investigation into the latest 
incident found that the prison service didn’t realise that the encryption 
option on the new hard drives needed to be turned on to work correctly.’ 




However, there are additional factors of risk for the protection of privacy in the MIP 
federated infrastructure. Following ‘Europe 2020 Flagship Initiative Innovation Union,’ EC 
funded research projects are strongly encouraged to contract out to the European private 
sector parts of the work for time and cost efficiency, for avoiding the waste of duplicated 
efforts and for boosting business growth. In this context, the MIP is subcontracting two 
areas of its work: privacy protocols29 and data federation30. According to the security 
experts who gave their opinions in our webinars and seminars, the subcontracting of the 
software for data anonymisation and data federation is introducing an additional level of 
uncertainty and associated risks. 
The second major legal challenge concerns the responsibility for controlling data. The 
legal experts we consulted were of the opinion that it would be wrong to assume that, 
since data never physically leave the premises of the local institutions (hospital, etc.) 
where they are managed, unless they are anonymised through de-identification and 
double-aggregation, the entire legal responsibility for controlling data rests with these 
local institutions. The view of the MIP is that, since the MIP never deals with data, but only 
with the results of queries and that it holds only depersonalised, standardised, normalised 
data transformed to be addressable by queries, it cannot be deemed a ‘data controller.’ 
However, in relation to current EU data protection law, the MIP projected architecture 
could raise the problem of ‘data processing by assignment,’ which is the European law 
term for the co-controlling of the data.  
According to European data law experts, in view of the MIP architecture, the legal entities 
that can be held responsible under EU law for data and human rights protection are the 
‘points of contacts’ between the MIP and the external world, especially as the MIP is not 
itself a legal entity. This means that the legal entity owning the point of entry into the MIP 
may be considered to be processing data by assignment, and thus sharing the data 
controlling responsibility with local institutions. The point of entry into the MIP is the HBP 
Unified Portal, developed and managed by EPFL, which provides access to all HBP 
Platforms. It is possible that in the future, once the MIP is set up and enters its operational 
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phase, the MIP may ‘spin off’ a private venture under the umbrella of an HBP Foundation. 
This private company would be in charge of selling and maintaining turnkey packages (the 
local servers’ hardware and software plus training, support and consultancy) to the 
hospitals and other institutions like pharmaceutical companies signing-up to participate in 
the MIP. The legal status of the various entities involved in the management of the HBP 
would then have to be thoroughly re-examined, as well as any significant change in the 
management and organisation of the MIP federated infrastructure. To address these 
challenges, we make a number of recommendations below for the information security 
architecture of the HBP. Many of these are already in development and/or being 
implemented, as a result of the discussions that form the basis of this report. 
3.2.2 Trustworthiness 
A focus on the potential legal challenges can lead to privileging technological fixes to the 
problem of privacy, which do not address the critical challenge of trustworthiness. 
Conforming to the law is necessary, but it is not sufficient. Projects developed in all 
legality can flounder because they fail to generate trust among the public and their users. 
In the domain of public health, a prominent and recent example of such failing has been 
the case of the NHS care.data programme (http://www.england.nhs.uk/ourwork/tsd/care-
data/). We now consider how the issues raised by the HBP MIP can challenge 
trustworthiness, according to the participants who were involved in the stakeholder and 
expert seminar in Copenhagen. 
There was a consensus among participants that trustworthiness is key to obtaining 
informed consent from individual participants. Ensuring trust is therefore paramount for 
the MIP to succeed. Identifying and collecting suitable data required for developing data 
mining algorithms has already proved more difficult than thought initially, due to the 
impact of privacy protection concerns on the strategy initially adopted by the MIP 
(anonymisation to circumvent the need to re-obtain specific consent). Moreover, if a 
process for re-obtaining consent is put in place, the risk is that given the opportunity, 
people could start to opt-out in large numbers. The resulting loss of research power could 
then be crippling for the MIP, and it is impossible to force people not to opt-out. While it 
may be far-fetched, one could imagine a scenario where, in the kinds of national health 
services that characterise European nations, opting in might be a condition for obtaining 
the health benefits of an insurance-based system. The rationale for this would be that in 
such population-wide insurance-based systems, everyone contributes, and risk and cost are 
distributed. Most of every Euro you pay for medical care in a socialised system is for you, 
but a tiny bit is also for everyone because it is used for public health.  
This argument, which is felt strongly by those who are directing the MIP, has an important 
base in moral philosophy, but the proposition that one should be obliged to share one’s 
private data as a condition for receipt of health care is a troubling one for many. 
‘Someone can predict whether you are pregnant or not by your shopping 
activities – it is done already.’ 
‘Would you object to the fact that with smart metering, your electricity 
company may know when you are getting a divorce before you know it 
yourself?’ 
- What do you think this big data feeding frenzy is about? 
- It is about prediction. 
- It is about optimising corporations’ bottom line by essentially no 
morally directed or ethically scrutinised fact-discovering strategy, at 
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all. It is looking for correlations that can then be exploited. 
- It is prediction and as we all know prediction is an inexact science … 
- The trouble is, it doesn’t have to be exact to be used, but even if it 
was exact, that doesn't solve all the ethical problems.’ 
Source: HBP-SP12 Stakeholder and Expert seminar, Copenhagen, 8-9 
October 2014 
The third vignette addressed the possibility of involving patients associations and support 
groups in collaborating with the MIP, turning the notion of informed consent from an 
obstacle to be overcome into a platform for active engagement. Although fear of 
discrimination and stigma has real foundations, evidence suggests that many patient 
groups and engaged patients would be keen to be involved in such a project. The 
pioneering example was that of AIDS activists when they fought to involve themselves into 
the medical governance of AIDS. AIDS patient groups are now controlling how experimental 
drugs are being used, which few would have dreamt of fifteen years ago.  
In an area closer to the MIP, at a recent international Huntington disease conference in 
Barcelona, people with the mutation have declared their genetic status and become 
among the biggest advocates for further research in Huntington disease; they have 
encouraged others carrying the genetic sequences predictive of HD to do the same and get 
involved. 31  However, there are significant differences between countries in terms of 
discriminatory attitudes and fear of stigmatisation. When the Alzheimer Europe organises 
conferences, in certain countries they find few individuals willing to stand up in public and 
say, “I have dementia.” This could have an impact on the representativeness of the groups 
collaborating with the MIP, with the possible self-exclusion of entire segments of the 
European population. In this context, and because the MIP research team is deeply 
convinced that securing the collaboration and involvement of patients and support groups 
is the way forward, we think that public engagement work with such bodies as Alzheimer 
Europe is necessary.  
3.2.3 Privacy and Big Data Expectations 
Legality and trustworthiness are common challenges to all projects involving human 
subjects’ data and in particular health records. The HBP MIP faces yet another kind of 
challenge, which is that of the expectations, and associated worries about privacy, that 
Big Data projects can arouse among various constituencies. 
The question of privacy was at the centre of the issues debated during the stakeholder 
seminar in Copenhagen, with diverse positions on the matter. One view was that there is 
currently a gap in the attitudes of people vis à vis how they relate to knowledge in the 
context of health and medical databases, and how they relate to knowledge collected in 
social media and the budding ‘internet of things’ (smartphones, smart watches, fitness 
apps, etc.). The number of mixed networked structures is increasing rapidly, and it is very 
hard to predict how these structures will develop and how attitudes will evolve with 
regard to privacy.  
Overall, participants in the seminar thought that attitudes towards privacy and individual 
health data are becoming more relaxed. However, a recent Science review summarising 
and drawing connections between diverse streams of empirical research on privacy 
behaviour highlights that people are very certain about the consequences of privacy-
related behaviours; that their concerns (or lack thereof) are very much context-
dependent; and that privacy concerns may be malleable and open to manipulation by 
commercial and governmental interests. 32  From this perspective, minorities with 
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psychological or psychiatric conditions may justifiably fear the possibility of discrimination 
and remain very keen on protecting their personal health records.33 It was also pointed out 
that in the area of human brain science in particular, patients could be rationally 
apprehensive about whether brain scans might, in the future, provide a window into their 
‘soul’ - their psychological make-up. 
Trust in those who would have access to or would use the data was considered to be a 
major factor that would influence people’s willingness to share what they would regard as 
‘their personal data’ through the MIP. This is despite the fact that, in the firm belief of 
those who have established the MIP, this concern is misplaced because the de-
identification and aggregation procedures ensure that no personal data are shared. The 
discussions in our webinars and seminars clearly showed that currently, this assertion is 
either not understood or not accepted, even by relatively expert stakeholders, and hence 
might be even less well accepted by patients and others contributing data to the MIP. 
Trustworthiness is all the more important since current data protection legislation, with its 
focus on personal information, is ill-suited to providing adequate privacy protection when 
it comes to Big Data applications. There, the risk may not be so much about identifying 
specific individuals than about associating identifiable groups of individuals with specific 
characteristics. This particular issue has been flagged in the report on “The collection, 
linking and use of data in biomedical research and health care: ethical issues” by the 
Nuffield Council on Bioethics, released in February 2015. 34  The Nuffield report also 
examines the important question of balancing individual privacy against public good. For 
individuals to be willing to relinquish some of their privacy by sharing their medical data, 
they have to trust that doing so will actually benefit the public; hence the importance of 
engaging publics in the work of the MIP at an early stage.  
In fact, technical difficulties may render some of these issues less significant, because it 
may be the case that much of the data stored in hospital and clinic records is difficult or 
impossible to process appropriately for use by the MIP. At this stage in the Project, the MIP 
has been experiencing technical difficulties in processing data sets from hospital providers, 
due largely to issues with the quality of the data held in hospitals (difficulty mapping local 
hospital records into the projected standardised MIP data management structure; 
heterogeneity and scale of the data sources; for brain images, major differences between 
research scans and the clinical scans performed in hospitals).35 Although such difficulties in 
standardisation have been anticipated, and may be circumvented by careful selection of 
variables to be extracted from clinical records, the strategy initially envisioned of relying 
extensively on historical data held in hospitals may not work out as well as initially 
thought; this particular reservoir of data, despite its anticipated potential use for the 
public good, proves difficult to deploy for the proposed research. Indeed the MIP is already 
exploring the possibility of utilising other data sources, such as those gathered in other 
research projects or in clinical trials conducted by pharmaceutical companies; indeed such 
data may present fewer difficulties for use, given the kinds of consent normally obtained 
in research.  
In view of the risks of malicious misuse that we have highlighted, we recommend the 
systematic exploration of technical scenarios for misuse, and that the testing and auditing 
of data protection arrangements. Such tests need to be conducted at regular intervals in 
the future, as the risks posed to privacy by the networking of data will evolve over time. 
These reviews will form part of the concerns of the Privacy Impact Assessment 
recommended below. 
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3.3 Recommendations 
The HBP Consortium is a large, decentralised, and distributed organisation that aims to 
build six ICT Platforms, and to make them accessible to the wider scientific community via 
the Unified Portal. In line with the conclusions reached at the Copenhagen seminar for 
addressing the major legal issues facing the MIP, we make the following technical 
recommendations concerning the Information Security Architecture, which must be a key 
element of the information security governance process for any large organisation, and 
which is increasingly seen as essential to the governance and management of IT.36 
 Provide for regular and systematic work on scenarios for misuse. Misuse can occur in 
many ways. For example, intruders with malicious intent have demonstrated that they 
have the capacity and the will to enter a variety of networked databases and to 
overcome cyber security provisions. It is therefore important to regularly update 
scenarios for misuse in the light of latest evidence, and ensure that the security 
architecture of the MIP is robust and protected to the greatest extent possible against 
misuse. 
 Set up an Information Security Architecture Partnering Project to the MIP. We 
recommend that an Information Security Architecture Partnering Project to the MIP be 
set up before the end of the Ramp-Up Phase. Preferably, it should be extended to the 
whole of the HBP if such provision is not already in place.  
 Conduct a Privacy Impact Assessment of the MIP before the end of the Ramp-Up 
Phase. Such an assessment should preferably cover the whole HBP (if such provisions 
are not already in place) since the point of entry into the MIP is the HBP Unified Portal 
developed by SP6 that regulates access to all HBP Platforms. 
 Evaluate the consent requirements for different functions of the MIP, giving priority 
to informed consent wherever possible. Despite technical procedures for 
anonymisation, it is ethically desirable and socially prudent to ensure that either broad 
consent for research use or full informed consent for specific use is obtained from all 
patients or research subjects whose data are to be federated and used in the MIP 
 Consider special issues that may arise in the use of data acquired from outside the 
EU. Where data are to be obtained from sources (hospitals, research organisations, 
pharmaceutical companies) outside the EU, special attention needs to be paid to 
ensure that appropriate informed consent has been obtained and is properly recorded 
and archived. Prior to any such data being utilised, a request for advice should be 
made to the Research Ethics Committee of the HBP, and data should only be used if it 
has their approval.  
 Establish protocols for engagement with patient, patient support and stakeholder 
groups regarding different MIP functions. Strenuous efforts should be made in all 
participating countries to involve patient associations and support groups. As a first 
step, the AIDS community’s involvement in medical research should be investigated, to 
evaluate how translatable it could be to dementia/Alzheimer for the MIP. The Work 
Package looking at user support and community building (WP8.5) focuses exclusively on 
three constituencies: pharmaceutical industry, research centres in mental health 
prospective and longitudinal studies, and clinicians. We recommend that the 
community building activities should be broadened to involve more diverse publics. As 
we have suggested above, overcoming possible prejudices and discriminatory attitudes, 
both general and country-specific, will require coordinated engagement work.37 
 Develop a Public Engagement and Research Dissemination Plan. Inspiration for public 
engagement and participation in research may be found, for instance, in the INVOLVE 





Report on future medicine_Website version Dissemination: PU  26-Jun-2015 Page 25 of 65 
 
initiative set up by the NHS in the UK, which has recently released guidance on the use 
of social media to actively involve people in research. Investigating these good 
practices and exploring their translatability to the MIP could be the goal of a HBP 
Partnering Project under FLAG-ERA.38 
 Create a Data Governance Committee for the MIP with a broad membership 
including representatives of users and the public. We recommend following best 
practice in biobanks and related organisations, by creating a Data Governance 
Committee, in order actively to involve various publics in the governance structures of 
the MIP. 
 Ensure a Research Audit structure that can identify, authorise and audit all users of 
the MIP. We recommend that a structure be developed to identify, authorise and audit 
all users of the MIP. Users would be given permissions and each research project 
application could be elaborated in collaboration between the applicant and a ‘MIP 
consultant’ who would help to define precisely the type of data required. The 
evaluation of each application would involve a privacy risk assessment procedure, and 
would weigh the privacy risk involved against the potential benefits of the research, 
before approving, rejecting, or requiring amendments to the application. This process 
would report regularly to the Data Governance Committee recommended above.  
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4. Disease Signatures: Foresight 
4.1 Background Scenarios 
The second set of social and ethical issues considered in this report relates to the search 
for disease signatures and how these, if found, might be brought into clinical use and what 
their societal impact might be.39 It should be pointed out that the MIP does not envisage 
the promulgation of such signatures for clinical practice until the operational phase of the 
HBP, and so formal plans and strategies for this aspect of their work are currently 
underdeveloped. To explore these issues, the Foresight Lab developed three more short 
narrative scenarios, which contributed to further stakeholder discussion in the 
aforementioned seminar organised in collaboration with the Danish Board of Technology 
(DBT), which took place in Copenhagen on 8 and 9 October 2014.  
4.1.1 Scenario 4: The Psychiatric Conundrum 
The MIP has been highly successful in identifying brain signatures of neurological 
disorders, especially Alzheimer’s disease and some other dementias, and pre-
symptomatic tests are coming into routine clinical practice to identify those forms of 
Mild Cognitive Impairment that are likely to progress to dementia. But a group of 
researchers working with the MIP now has claimed to be able to identify the disease 
signature of depressive disorders and are proposing that this be developed into a 
screening test to be used in early adolescence. Their University has put out a very 
optimistic press release claiming that ‘depression has been proved to be a brain 
disease; tests developed by our researchers can now predict who will get depressed, 
and a new generation of drugs is just around the corner.’  
This scenario considers some of the routes to success, including those involving the 
aggregation of data from a range of sources outside European hospitals, and the 
combination of methods. It also considers the implications of the extension of the 
identification of brain signatures of disorders from neurological disorders to the much 
more contentious area of common psychiatric disorders, and the likely pressure for 
screening and pharmaceutical intervention. To what extent are the controversies 
suggested in this scenario realistic? If so, what are the best routes to address them? What 
might be the implications of developing screening when only probabilistic indicators 
derived from a small sector (white males) of the general population are available? Will the 
identification of ‘brain signatures’ end the debate about social versus biological causes of 
mental illness? 
4.1.2 Scenario 5: The Award Ceremony 
The highly successful Medical Informatics Platform has been funded by the European 
Union for another 10 years to continue refining and validating disease signatures that 
have come into the public domain and, indeed, routine clinical use through the 
combined efforts of HBP researchers, pharmaceutical companies, social media 
companies, organised patient networks, and bioinformatics experts. But success brings 
its critics and its dilemmas. 
This scenario presumes that limited success in establishing identifiable disease signatures 
drives the need for more data and for more refined information to make the disease 
signatures less probabilistic, and more precise and useable in clinical work with 
individuals. It considers some of the ways in which this search for more and better 
information might proceed and some of the costs. And it addresses some of the key issues 
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concerning the pathways to translation via alliances with commercial companies which can 
take the research from the lab into the clinic. It also raises the possibility that disease 
signatures might be used in the criminal courts in determining culpability (comparable to 
the disputes in the USA about the use of genetic evidence and brain scans in criminal 
trials). 
4.1.3 Scenario 6: Beyond the Brain 
It is five years after the Human Brain Project formally ended, having accomplished 
some minor advances in neuroscience and neuromorphic chip design. However, 
although various disease signatures have been proposed, validation testing and further 
research shows examples of healthy persons with the same brain signature as those 
with clear manifestations of the disease in the clinical setting. What would be the 
implications of this apparent inability to extrapolate from brain signatures to the 
experience of disease? More data seems to be the solution, but how can the rich 
qualitative environmental and experiential data that seems pertinent be made 
compatible with the advanced techniques of data mining required to identify brain 
signatures? 
This scenario considers the possibility that the disease signature identification task set by 
the Medical Informatics Platform may prove too complex to resolve within the very short 
funding cycle of the HBP. However the scenario is optimistic in that it suggests that the 
HBP has built the Project in such a way that the medical research community and young 
people still feel inspired to take up the challenge. What kind of data collection standards 
could be comprehensive yet flexible enough to cover the diverse social and geographic 
situations from which it will be collected? What are the research investment choices that 
the HBP can make that will benefit the medical neuroscience community even after the 
HBP has ended? How might the HBP legacy relate to public health strategies in the regions 
of the world where individuals widely make use of treatments outside the formal medical 
system? 
4.2 Emerging Challenges 
Many have suggested that the inability of research to identify the biological basis of 
mental illnesses has led to a lack of progress in developing targeted treatments for 
psychiatric or neurological disorders. With the strength of modern computing, it is hoped 
that more specific knowledge of the biological basis of disease can be identified from the 
cross analysis of large amounts of patient data, genetic, neuro-imaging, lifestyle and other 
forms of data federated together in the HBP Medical Informatics Platform. The suggestion 
is that this biological knowledge, linked to a greater understanding of the specific 
individual, could be used to create healthcare specific to the circumstances of the 
individual. This is the approach known as personalised medicine (elsewhere termed 
stratified or precision medicine) which some believe would transform treatment 
possibilities and the identification of treatment targets for patients with ‘brain disorders.’  
The first target for work using the MIP is neurological disorders, and dementias in 
particular. Many researchers at the HBP and elsewhere believe that disorders currently 
classed as neurological share many basic mechanisms with those currently classed as 
psychiatric. Therefore, this approach could illuminate common mechanisms and potentially 
lead to a radical reformulation of our classificatory systems. Yet, as we have suggested, a 
number of ethical and social dilemmas are raised by such approaches. 
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4.2.1 Recognition and Interpretation of Statistical Clusters within Data  
One approach used by the MIP to identify disease signatures analyses data in three stages: 
categorisation, clustering, and classification. Using this “3-C strategy”, an initial proof of 
principle study by researchers within the MIP sought to develop early diagnostics from 
groups of biomarkers.40 As an initial proof of concept study, available aggregate data from 
the Alzheimer's Disease Neuroimaging Initiative (ADNI) was categorised into three types: 
the patient's assigned disease diagnosis, clinical measurements and potential biological 
markers (for example, genomic or brain imaging data). 41  In the next step, a learning 
algorithm was used to find hidden structure in the data; that is to say, to identify 
'clusters.' The number of clusters was decided using a combination of existing medical 
knowledge and looking at the size of gaps between potential clusters. In the case study, 
there were 10 clusters (10 new “clinical manifestation classes”) that were to be linked to 
the clinical measures. In the final classification stage, potential groups of biomarkers were 
then linked to these 10 new classes. The 10 sets of grouped biomarker values ranges (each 
set linked to a clinical manifestation class) were then set out using hierarchical decision 
trees, so that they could easily be described in a clinically relevant way to assist diagnosis.  
A first problem with algorithm-based approaches emerged in our discussions with our 
informants: How can we be certain of the results? The clusters, which are derived by a 
form of ‘machine learning,’ are unlikely to be self-explanatory to clinicians, patients and 
other stakeholders, who may well need to be convinced of the precise reasons that the 
computer has delivered particular clusters. In the seminar discussion, participants raised 
concerns that decision-making was here being embedded in technical processes. Would 
there be a human in the room when a decision was being made? Which human? Our 
informants believed that human beings must make clinical decisions, rather than 
delegating them to algorithms. 
When clustering results indicate new ways to predict disease, clinical research will then be 
required to test these results. In some cases, the association of a person with a statistical 
cluster will suggest that they may at some unspecified time in the future develop a 
problem or that their relatively minor symptoms are precursors for a fully-fledged mental 
illness. The verification process for proposed disease signatures in some circumstances may 
take years or simply continue to be ambiguous. More fundamentally, for those seeking a 
plausible biological account of the aetiology of each disorder, the causal reasons for 
associations will not be apparent in the results of statistical clustering. Further, there is no 
reason to believe, a priori, that statistical clustering maps onto sets of biological 
pathways. The existence of statistical clusters may provoke space for new theorising and 
investigative research into mechanisms. For some mechanisms, where a particular 
biomarker can result in any of several different disease presentations, 42  it may be 
particularly difficult to identify causal pathways from the neurological level to the 
presentation level given the current state of understanding of the brain. These statistical 
approaches may be linked to craft-based medical health practices that emphasise the 
study of the developmental pathways in disease progression, in order to develop practical 
healthcare responses. Indeed, one webinar participant argued that although Alzheimer’s 
disease patients would be thought of as having a neurodegenerative disorder, 
psychoanalysis is still very effective in slowing progression and maintaining memory in the 
first phase of the disease.43  
4.2.2 Predictive Medicine  
Advocates of this approach are hopeful that it will enable better diagnosis, and hence 
targeting of treatment. They also hope that it will prove useful for prediction, that is to 
say, for early identification of a disorder and intervention for the purposes of prevention, 
or at least mitigation. Thus, for example, testing at the time of first mild symptoms or first 
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behavioural problems may lead (through the use of biomarkers) to the conclusion that the 
individual has a higher than average probability of developing a psychiatric or neurological 
condition, and hence to early intervention. 
Predictive medicine raises a number of concerns in that it inverts the normal relationship 
between doctor and patient.44 Traditionally, a patient consults a doctor because they have 
symptoms and seek treatment. In preventive medicine, however, an individual who is 
subjectively healthy is advised that they may need to undertake a regime of preventative 
intervention, usually medication, so that some future illness or predisposition to an illness 
does not manifest itself. This preventive intervention treats not an illness, but a risk of 
illness that has often been established by epidemiological studies. Recently, however, with 
developments in genomics and biomedicine, these risks are established by identifying 
biomarkers that are associated, probabilistically, with an increased likelihood of 
developing a disease at some time in the future – identifying a susceptibility or 
predisposition to a disorder.  
Integrated analysis of many data sets in large populations via the MIP could greatly 
increase such predictive powers. Nonetheless, in the view of many of those involved in our 
discussions, the predictive powers emerging from large scale statistical work associating 
biological, clinical and lifestyle data will remain ambiguous, and based on probabilities 
rather than certainties. Further, in many cases, they are likely to be insufficient definite 
causal mechanisms to explain the statistical associations. Commercial applications of 
preventative medicine may also complicate the issue, perhaps suggesting to the proto-
patient that their diagnosis, and the treatment offered, is not so much for their benefit as 
for the commercial benefit of the innovator.  
The view emerging from our Foresight activities is that it is necessary to consider the 
rights of the patient in the patient/health care provider relationship that might develop 
around these new predictive technologies. An understanding shared by clinicians and 
patients of issues of risk and probability amongst both clinicians and patients, and 
relationship of trust between patient and doctor, will be crucially important if advances in 
mental health care knowledge from such research are to gain public acceptance in clinical 
practice. 
Hence, when considering the ways in which statistical classification from data mining and 
clustering may give rise to new diagnostic categories and procedures, and novel forms of 
clinical decision making, our interlocutors suggest that it will be important to link a broad 
range of communities into this discussion and make the process as understandable as 
possible. If decisions with potential societal and cultural impact are made only on the basis 
of medical expertise, this already shifts the doctor/patient relationship in a more 
technocratic direction. This may also fail to generate the trust necessary for public 
acceptance.  
Seminar participants agreed that it was important to consider how to make the difficult 
mathematics of statistical clustering intelligible to a broader range of stakeholder publics, 
so that the latter might be included in a debate about the implications. Evidence from 
related public dialogues and investigations of public responses to the prospect of 
‘personalised medicine’ suggest that many people – at least in publicly funded health 
services – have much trust in their medical practitioners and will readily delegate their 
authority to them. However, there is evidence that some groups are less trusting; younger 
people and those from ethnic minorities, who are concerned about possibilities of 
discrimination in the allocation of treatments on the basis of such tests.45  
In addition, there is a long history of disquiet about relations between psychiatrists and 
patients, and much evidence that the trust placed in non-psychiatric practitioners is less 
readily obtained, or easily forfeited, in this particular medical specialty, perhaps for 
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understandable historical reasons. Further, there are often concerns expressed about 
commercial involvement and motivation, which can undermine the trust that seems so 
readily placed in doctors. Hence, there is an important role for an engagement process in 
establishing institutional trust and ensuring transparency of the process by which these 
novel approaches have been developed, the methods for their application in clinical 
settings, and their implications. 
4.2.3 What is the Difference Between a Disease Signature and a Brain 
Signature? 
Many of the participants in our discussions raised the question of when a particular pattern 
of data that correlates to a brain signature should be taken as an indication of a disease. 
Neurobiological differences do not in themselves indicate disease status. This raises the 
question of who should decide at what point variance from a norm indicates the presence 
of a disorder, especially in cases where the issue is one of prediction and preventive 
intervention. It is clearly very important that such questions are recognised and debated 
openly, not just with psychiatric and neurological clinicians – many of whom have 
conflicting views on these issues – but especially with affected or potentially affected 
patient groups – for example, where parents with a particular psychiatric or neurological 
condition might be concerned about whether their children are going in turn to develop 
such a condition. 
In this context, linking with affected and potentially affected communities can enable 
them to play a role in the development of definitions and treatments. In particular, our 
participants argued that working with patient and disability groups will be of particular 
value in improving the outcomes of this process. Participation by affected communities 
may provide insights for effective implementation that researchers or clinicians might not 
initially see. While it is important to consider concerns with possible stigmatisation of 
persons with abnormal brain signatures, there are also potential opportunities for 
identifying neural difference and protecting those persons with it. For example, many 
would argue that the identification of dyslexia and subsequent procedures to recognise this 
neural difference and protect those with it from unfair practices or discrimination had 
positive consequences for those so diagnosed.46 Several of our participants argued that we 
need to learn from history, and to work with potentially affected communities, to ensure 
that identification of brain signatures in the Human Brain Project in conjunction with 
affected communities will lead to positive consequences rather than stigma and 
discrimination. This is clearly a case where outcomes depend on how brain signatures will 
be communicated to the public. Seminar participants suggested the need for a 
communication plan that was audience-specific, with different strategies adopted for 
communication with statisticians, clinicians, patients, the public, journalists, and science 
policy professionals.  
A further issue raised by one of our webinar participants concerned the potential impact of 
such research on ‘cultural ability expectations’ – i.e., the ways in which beliefs about the 
value of certain abilities enable access to resources such as income, political influence and 
employment. He pointed to historical evidence that changes in expectations about human 
abilities can be triggered by scientific research, technological development or other 
events, and might even shape decisions about which types of abilities should be valued in 
the future. He suggested that it was important to undertake research in this areas using a 
disability studies lens.47 Many different developments are envisioned as contributing to 
personalised medicine: active health consumers, ‘the quantified self’, patient-driven 
healthcare and research models, as well as health social networks and participatory 
medicine.48 We need to consider the potential implications for ability expectations of such 
developments in predictive and personalised medicine.49  
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4.2.4 Clinical Use and Acceptance of Disease Signatures 
Even if it is possible to identify brain signatures of disease that are potentially useful for 
clinical practice, the process of translation will be lengthy and complex. The incorporation 
of relatively simple new research findings into clinical best practice guidelines typically 
lags the publication of research findings by several years and the widespread uptake of 
new practices usually follows more than 15 years after the initial research was published.50 
The kind of foundational change in how we diagnose and treat mental health problems 
suggested by the MIP may take much longer to incorporate. The process of transition to 
personalised medicine in complex clinical health systems requires careful consideration.51  
Clinical acceptance of new research is a slow process. Early claims of success in a research 
setting can only be judged in the clinical setting over time. Rapid change in complex 
institutions such as national health care systems can potentially result in a reduction in the 
overall quality of health service, especially if change is implemented from above before a 
broader consensus has been agreed. System-wide changes that are linked to a change in 
the status of those involved in health provision (e.g., if diagnosis on the basis of brain 
signatures rather than clinical judgment was linked to deskilling of mental health 
professionals) may lead to resistance. 
As has been argued in work on personalised medicine in other contexts, developments in 
medical training for clinicians will be required to integrate the use of disease signatures 
into clinical health. However, the feedback process needs to be bidirectional - the 
integration of clinical knowledge and practice into the design of health technologies to 
support clinical use of disease signatures is crucial to their success and acceptance. Even 
simple things such as the interface design for a computer system should continue to 
support clinician practice and professional responsibility, or they might contribute to a 
gradual deskilling of health professionals. There is a danger that this might remove not 
only the doctor from health decision-making but also the patient, as the latter relies upon 
subjective interaction with the former to participate in decisions about their own health. 
Algorithm-based decision aids can support doctors and other health professionals, but it is 
unlikely that they could replace them, even over longer time scales than are considered in 
this report. 
4.2.5 Personalised Medicine: Implications for Knowledge Infrastructure  
There has been a gradual move from one-size-fits-all ‘blockbuster medicine’ (i.e., 
medicine effective for the whole population of those diagnosed with a disorder) to more 
stratified medicine (where treatment is specific to different groups of persons with similar 
biological responses to treatment). While stratification relates to the division of potential 
patient groups into sub-groups according to their likelihood of responding to particular 
treatments, personalisation implies tailoring treatment to each specific individual. While 
personalised medicine was initially thought of specifically in relation to genomic markers, 
the definition has now broadened: “consideration of individual characteristics, molecular 
or otherwise, at every stage of medical practice, from prevention, diagnosis, therapy to 
monitoring.”52  
There are currently no clinically validated biomarkers in mental health that could underpin 
a personalised medicine regime in psychiatry or even in relation to the dementias. 
However, the search for brain signatures is certainly linked to an aspiration for 
personalised medicine; hence it is worth considering various images of what a future 
regime of personalised medicine might look like. 
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Figure 2: This illustrates several layers of organisation around individual patients in a 
form similar to layered structures in geographic information services (GIS) mapping. 
Image from Toward Precision Medicine: Building a Knowledge Network for Biomedical 
Research and a New Taxonomy of Disease, National Academy of Sciences, 2011 p15. 
In current conceptions of personalised medicine, symptom-based disease taxonomies will 
give way to data-rich biological characterisations of individuals in various stages of their 
lives. Every disease is unique to the individual, although similar patterns drawn from large 
amounts of data from other individuals help to explain how the disease manifests itself 
within the individual in question. In this vision, randomised control trials (RCT) would 
gradually be replaced with more in-depth studies; first of more stratified groups, but 
ultimately of one person, coupled with in silico modelling. Biological signatures would be 
developed for the various progressive stages of a disease, and treatments developed and 
targeted to these biological substrates. But, as was pointed out in our discussions, while 
some contrast ‘personalised’ medicine to public health preventive medicine that focuses 
on widescale changes in health environment, there is no reason in principle that social 
determinants could not be part of the personalisation data mapping structures. As 
indicated in an earlier chapter, there is already much on-going discussion about the 
implications for medical research ethics, and it is important to consider what could be the 
HBP’s contribution to this larger discussion. 
Regardless of whether stratified or personalised medicine will become technically possible, 
there are certainly challenges relating to how this might be implemented within existing 
health care systems. Participants in our webinars and seminars pointed to many of these 
changes. Challenges include data integration and interoperability, gatekeeping of data, 
and protection/privacy. While the previous section of this report discusses many of these 
issues from the specific perspective of the MIP, we should note that, as big data 
aspirations become more central to medical and health research, with a wider move 
towards personalised medicine, these issues will need be revisited more intensively. Our 
participants also pointed to other necessary changes. There is even now a greater need to 
develop data literacy amongst a greater number of users. Researchers, doctors and 
patients must better understand what big data can and cannot do. Many of our 
interlocutors stressed that, for doctors, algorithm-based decision aids should aim to 
support rather than replace them.  
Furthermore, there is the question of who has claim to the data. Some argue that in a 
democratic health regime, patients should have access and control of their own data.53 
Inclusion of patients in their own data evaluation is not only an issue of patient rights. It 
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may also improve data analysis. For example, patients might be able to recognise which 
data might have been left out of a particular data architecture; in particular, the types of 
things that are hard to digitise.54  
4.2.6 Patient Involvement 
Early ‘upstream’ involvement of patients in the translation of the research of the HBP to 
clinical medicine process may be able to address potential problems that would arise 
without their involvement. Managing patient expectations and giving them all the 
information up front (e.g., where their data could ultimately go) is important. There is a 
need for good quality information for lay audiences, and working with patient 
organisations can be helpful in ensuring that patients are fully informed. Many patient 
organisations, such as the Alzheimer’s Society in the UK, have developed effective ways to 
engage patients and/or their families in the research process. As indicated by one of our 
informants, many patients start off being involved in an observational study and transition 
to being part of an experimental study. However, patient involvement is not merely to be 
encouraged in the form of active commitment to being research subjects, important as 
that might be. Involvement of patients as participants in research decision-making or 
strategy is also important; for example, being on or advising governance committees.  
We suggest that, to the greatest extent possible, involvement of patients prior to the 
clinical translation process itself is desirable. Communication should be a two-way 
partnership with patients who may be able to help in developing protocols and research 
policies, and will be knowledgeable about issues of data use, governance, and de-
identification. Better communication with patients naturally allows them to transition 
from being informed research subjects to the next level of assisting with research 
governance. As the MIP moves towards developing its work on brain signatures towards 
clinical applications, they might consider patient inclusion in an on-going monitoring or 
‘steering’ group. In addition to potential benefits to the research process this gives 
patients and other stakeholders’ confidence in the integrity of the study. Ultimately, all 
evidence suggests that patient endorsement is paramount for success.  
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4.3 Recommendations 
Many of the social and ethical challenges that the MIP faces can potentially be alleviated 
by having a strong consultation and engagement process with communities that may be 
affected by the work of the HBP. Integrating a broad range of communities and 
stakeholders into the research process of the HBP MIP (in some cases, with the aim of 
building long-term working relations) can potentially improve the quality of HBP research 
methods, outcomes, and their translation into future health technologies and clinical 
practice. Thus, on the basis of our Foresight work on disease signatures, we make the 
following recommendations:1 
1) Include patients and clinicians in a research advisory capacity. Remember that 
communication is two-way. Consider patient and clinician inclusion on an advisory 
group. In addition to assisting in the translation of research results into clinical 
practice and new health care technology, this body might help in developing research 
protocols and data usage protocols. 
2) Address implications for clinical practice; in particular, by engaging clinicians in the 
assessment and verification of disease signatures and their utility in clinical 
applications. 
3) Provide more information on what big data can and cannot accomplish in disease 
signature medicine. Algorithm-based decision aids can support doctors and other health 
professionals, but not replace them.  
4) Address implications of disease signatures for clinical ethics. 
5) Let patients know up front how their data might be used – covering all the different 
possible research uses. Consider to what extent patients will have control of and access 
to their own data. Consider how incidental findings will be handled.  
6) Reflect on the use of brain signatures in the identification of pre-clinical 
susceptibilities. 
7) Facilitate discussion and solicit input from user and stakeholder communities on the 
development of disease signatures that are clinically effective and socially acceptable. 
This is especially important where such signatures may be used in a pre-clinical phase, 
i.e. before a disorder is manifest or subjectively experienced by a patient. The 
involvement of clinicians and patients in the interpretation of results is especially 
important here. 
8) Ensure awareness that neural difference does not equal brain disease. 
9) Consider how brain signatures will impact upon cultural expectations about people’s 
ability. Will this create more or less security (in self-identity, employment, etc.) for 
differently abled people? How will brain signature impact upon neural diversity? 
10) Develop effective communication strategies to explain the potential clinical and 
research uses of brain signatures to the public at large and other audiences. 
11) Develop a communication plan for complex science, allowing for different possible 
interpretations. This could benefit from being audience-specific: statisticians, 
neuroscientists, clinicians, patients, legal and policy professionals, journalists and the 
public at large all require different types of information to understand what we know 
                                            
1 These are numbered in sequence with the recommendations given in Chapter 3. 
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about unique brain data patterns and how this knowledge can best be used to improve 
human health and well-being. It may also be important to communicate what limits our 
knowledge has and what we can’t do with brain signatures. 
12) Consider the wider implications of moving to a brain-based understanding of disorders. 
13) Observe how new findings are interpreted by researchers, clinicians, pharmaceutical 
companies, media, public opinion and the legal system. Some suggest that these 
developments may raise questions about what it means to be human. 55 History shows 
that any such changes are slow, complex and dependent on many other social and 
cultural conditions. Nonetheless, there is a role for historical, philosophical, legal and 
anthropological enquiry into the medium- and long-term implications of the advances 
in our understanding of neural processes that will be brought about by the new brain 
projects.  
14) Link with other research communities and relevant regulators to develop appropriate 
pathways for translation of research to clinical applications. 
15) Develop a detailed strategy for a translation pathway to clinical use as the work of the 
MIP moves toward clinical applications. This will enable progress toward 
personalisation in psychiatric and brain disorders. 
16) Consider the implications for public trust and support of the HBP, of the future 
intended commercialisation of the findings to generate employment and wealth 
creation. 
17) Consider how early stage research and development can be better directed towards 
publically desirable outcomes that address major societal challenges, as we have seen 
how public trust can be easily forfeited if biomedical research is seen as primarily 
directed towards commercialisation and private profit rather than public good.  
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6. Annex 1: The Scenarios 
6.1 Data federation and privacy 
6.1.1 Scenario 1: The Price of Success 
By 2024, the HBP Medical Informatics Platform has succeeded beyond expectations. 
The data federation protocol has been widely accepted by hospitals, and large amounts 
of clinical data have been federated, without the need to obtain individual consent 
from ‘data subjects.’ Over the past few years, despite the significant human and 
material investment required, research hospitals as well as general hospitals across 
Europe have been flocking to enrol as collaborating institutions to give their 
researchers and clinicians access to the wealth of resources offered by the Platform. 
However, wide adoption brings some sloppiness of procedures. 
‘Today is 21 September 2024, and it promises to be a momentous day in Mia’s young career 
as an ambitious lawyer. This is her conviction, anyway, as she slaps the alarm clock off.  
Mia has picked World Alzheimer’s Day to file her first ever class action lawsuit. It will send 
a message that the media should love, and that should make her career. She is going to 
file a class action lawsuit in the European Court of Justice against one of the largest 
general hospitals in the country, for violation of the European data protection law. Mia 
thinks back on the events – unfortunate for some but lucky for her – that have made it 
possible.  
A year ago, there was a short story in the news that caught her attention. The identity and 
health records of an early onset Alzheimer’s patient had been made public through an 
alleged blunder at the hospital in which neurology service she was treated. The diagnostic 
capacities based on brain signatures that had been pioneered by the Human Brain Project 
were now being widely used in clinics for the early identification of neurodegenerative 
disorders based on brain signatures, and in this case, the diagnostic brain signature pointed 
at a specific type of dementia that was highly correlated with an inheritable genetic 
marker.  
Soon after the information about her mother’s condition was in the public domain, her 
only daughter was made redundant on supposedly economic grounds and got into trouble 
with her mortgage-protection insurance for not having divulged her mother’s condition. 
Mia had contacted the daughter as a result of the story, pitching to her the possible 
benefits of filing a suit against the hospital, and discovered that there was scope for much 
more than an individual lawsuit. Her potential client’s misfortunes originated not so much 
from a blunder than from a weakness in the hospital data management architecture, which 
meant the problem could occur again. The weakness could be traced to the fact that the 
anonymisation protocols established by the MIP some years before had apparently been 
inadequately implemented by the hospital database manager, so that unfortunate cases of 
individual re-identification could occur, exposing entire families through genetic linkage. 
To add to that, patients had never been made aware of this use of their data or been 
asked for their consent.  
At this point, Mia had felt that she had the makings of a highly successful landmark case, 
and one that would question the very legal and ethical foundations of this new diagnostic 
procedure.’ 
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6.1.2 Scenario 2: The Costs of Early Adoption 
By 2024, the HBP Medical Informatics Platform has achieved only partial success in 
getting European hospitals to collaborate. Only a few research hospitals are 
participating and the MIP has entered into partnerships with other, non-European brain 
projects as sources of research data. 
‘Today is 9 November 2024, and it promises to be an utterly nightmarish day. This, 
anyway, is Paul’s conviction as he swallows the last dregs of his coffee and nervously 
makes his way towards the boardroom. It is the first time in his seven years as chief 
executive director of one of the country’s prominent teaching and research hospitals that 
he has so dreaded attending a meeting with the Board of Trustees. In all likelihood, before 
this is over there will be blood on the carpet and it will be his. How could things have 
turned out so badly?  
In 2015 when Paul had engaged into a partnership with the Human Brain Project, to make 
his establishment one of the pilots collaborating research hospitals to their Medical 
Informatics Platform, his daring strategic move had received full approval from the Board 
of Trustees and had been hailed as ‘visionary’ by expert commentators. But the idea of a 
European public hospital federated infrastructure is now history. For the few European 
hospitals, like his, which became involved in the early stages, the investment has turned 
out to be considerable. This has dissuaded other hospitals from collaborating. As a result, 
the private contractors who were providing the local servers bundled solutions have 
announced that they will soon stop maintaining the dedicated software because they have 
sold too few units.  
Therefore, the hospital is going to be left with costly dedicated machines that are difficult 
to put to other uses. And to add to the pressure on the hospital management to pull out 
and write the whole thing off as a bad decision, their ethical board is less than happy to 
see them associate with a venture that has become controversial. This is in part because 
the MIP has revised its strategy, and is now using data from hospitals outside the EU, which 
have been less concerned about matters such as data protection and individual consent: 
the volume of data available in this way has made it less important to collaborate with 
European hospitals, but at the price of ethical and political controversy.’ 
This scenario is concerned with the possible implications that the failure to enrol a 
sufficient number of European public hospitals could have for the MIP and participating 
institutions. It develops a set of ethical and economic consequences that could impact 
hospitals that have joined the MIP. What changes in strategic choices could such a partial 
failure mean for the MIP roadmap? What could be the consequences for other actors of 
the wider MIP, including its sub-contractors? What steps could be taken to ensure that the 
‘early joiners’ do not get penalised by possible changes of strategy? And what might be 
the implications of the MIP, and the HBP, using data that comes from countries and 
regions whose ethical protocols are widely considered to be less robust? 
6.1.3 Scenario 3: The Citizen-Patient Alternative 
By 2024, the HBP Medical Informatics Platform has failed in its objective of enrolling 
hospitals to collaborate. Despite sophisticated anonymisation protocols, getting ethical 
approval for accessing existing patient data without their expressly informed consent 
has proven to be a fatal hurdle. Another major cause for the difficulties of the MIP’s 
partnering with hospitals was that the overall investment proved very costly, while the 
returns in terms of clinical benefits were dubious. 56  In the meantime, another 
consortium of neuroscientists has chosen a different strategy that is proving successful, 
but this strategy also has its downsides. 
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 ‘Today is Friday 23 April 2024, and the end of a week which started as an ordinary week 
for Gert but has turned into a life-changing decision-making ordeal. Having turned 50 a 
few weeks ago, he got treated through a comprehensive check-up courtesy of the National 
Health Service, and he met his General Practitioner first thing on Monday morning for the 
routine post-results feedback – except, it ended up being not so routine. The blood exam 
testing for the likelihood of his developing some form of dementia in the next five to ten 
years has proved positive. This was a shattering blow to his retirement dreams. But 
although Gert’s GP has been very professional in his advice, Gert would never think of 
relying solely on the NHS diagnosis. The NHS blood testing is all well and good, but he 
wants to have access to more cutting-edge diagnostic and monitoring tools than those 
available through the general public health services.  
Gert has heard of an EU-wide project that was been set up a few years ago, the Human 
Brain Project, but it appears that although research is still going on, the diagnostic 
procedures have not become generally available for clinical use, as few hospitals have 
agreed to participate, and there were some kinds of legal controversies – Gert does not 
quite understand why. Despite the best efforts of its public engagement work, the Human 
Brain Project has become bogged down in controversy, much of it coming from civil liberty 
groups and other radical critics, who have also suggested that its real motives are 
economic, as it has not made its findings public and has focussed on developing 
intellectual property and collaboration with private corporations who are charging 
exorbitant amounts for the use of the tests.  
However, Gert has found other options by surfing the websites of patient support groups. 
These are linked to a new extension to the EU Biobank, which has been developed by other 
neuroscientists in close collaboration with patient groups across Europe, and where 
thousands of patients have agreed to all their clinical records and samples being stored 
and analysed, with full individual consent, and where results have been very positive.  
Researchers have worked closely with patients groups and with clinicians to overcome 
barriers of mistrust and uncertainty about the meaning of the results, to ensure that the 
full benefits of early diagnostic and preventive therapies are available in the clinic. But 
because of the costs involved in collecting and processing the data, in particular the brain 
images that have to be research-grade, there is a selection process to get enrolled.  
It seems that patients’ support groups are acting as gatekeepers, and here is the small 
silver lining: because of his prospects of getting early onset dementia, Gert has a very 
good chance of getting enrolled. But still, this is an elitist process and only those who 
happen to have a powerful and well-resourced patient group to represent them and ‘their 
condition’ have been able to access this technology: the prospects of this diagnostic 
technology becoming routinely available for less ‘fashionable’ conditions and in every 
general hospital in the EU are remote. 
This scenario considers the possibility that the MIP could fail at implementing its planned 
federated infrastructure of public hospital, and explores the idea of an alternate 
distributed infrastructure, implemented with the collaboration of patients and patients 
support groups. How could such an alternative model develop? How could it interface with 
the general public health services and in particular the public hospitals? What would be 
its economics? Would it represent a preferable model to be adopted by the HBP? 
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6.2 Disease Signatures 
6.2.1 Scenario 4: The Psychiatric Conundrum 
The Medical Informatics Platform has been highly successful in identifying brain 
signatures of neurological disorders, especially Alzheimer’s disease and some other 
dementias. Pre-symptomatic tests are coming into routine clinical practice to identify 
those forms of Mild Cognitive Impairment that are likely to progress to dementia. But a 
group of researchers working with the MIP now has claimed to be able to identify the 
disease signature of depressive disorders and are proposing that this be developed into 
a screening test to be used in early adolescence. Their University has put out a very 
optimistic press release claiming that ‘depression has been proved to be a brain 
disease, tests developed by our researchers can now predict who will get depressed, 
and a new generation of drugs is just around the corner.’  
‘It was Saturday morning in Heidelberg in November 2020, and Philippe was still recovering 
from the late arrival of his flight to Frankfurt and the long transfer by train – he wondered: 
why on earth did they choose to have the press conference here? In fact, he was rather 
dreading the whole thing.  
Philippe’s group had shifted the MIP into a new phase. It had always been the belief of the 
directors that they could find brain signatures not just for neurological disorders, but also 
for psychiatric diseases – the goal that had eluded researchers for so many years. But his 
group had done it, when at last they had enough data from European hospitals, 
supplemented by some collected from other sources, and driven in part by hypotheses 
from existing research identified using the HBP’s own platforms – including some hitherto 
obscure mouse data, and some reports from China – based on work with higher primates 
unfortunately – together with brain mapping data from a large cohort recruited from the 
favelas in Rio by a contract research organisation (very economically he was delighted to 
say). Data integration was paying off, and although the ‘hypothesis free’ route of data 
mining had not generated results for psychiatry, they had combined ‘top down’ and 
‘bottom up’ and it worked.  
The results were probabilistic, of course, but using a retrospective approach to their 
longitudinal data, they had shown that they could predict at age 14 with 70% accuracy – in 
white males only at present – whether an individual was going to have developed a major 
depressive disorder by 25 – well actually a subtype of major depression, as the condition 
had been subdivided as a result of neurobiological work undertaken by the National 
Institute of Mental Health in the USA.  
Now, there was no doubt that depression was a neurobiological condition with a strong 
genetic component – those who claimed that it was environmentally caused, or a response 
to misfortune, or a reaction to unemployment were just plain wrong. But he could not 
understand the response – the organisers of the press conference had warned him that 
there were to be big demonstrations from protesters, ranging from scientologists to 
patients groups, and he had received several abusive emails – this seemed to be a very 
sensitive subject in Germany, for some reason.  
Maybe he had been unwise to suggest that this could lead to a programme of population 
screening of schoolchildren for the disorder and early intervention – but surely prevention 
was better than cure, and if these kids could be given antidepressants to ward off the 
depression, what would be wrong with that? Especially since his group had entered into a 
very lucrative agreement with a large pharmaceutical company to develop a whole new 
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generation of antidepressants which would be prescribed after the identification of the 
brain signature – these would be smart drugs, not like those old dirty SSRIs, with all their 
side effects – they would really target the biological basis of the disorder. Public health 
officials were already excited – think of the effect of these new treatments on the ‘burden 
of disease’ – especially in less developed countries where all those faintly ridiculous talking 
therapies were not available. Like it or not, these are the facts and they will have to live 
with them, he said to himself as he pulled on his trademark black tee shirt and jeans and 
slung his leather jacket over his shoulder.’ 
This scenario considers some of the routes to success, including those involving the 
aggregation of data from a range of sources outside European hospitals, and the 
combination of methods. It also considers the implications of the extension of the 
identification of brain signatures of disorders from neurological disorders to the much 
more contentious area of common psychiatric disorders, and the likely pressure for 
screening and pharmaceutical intervention. To what extent are the controversies 
suggested in this scenario realistic? If so, what are the best routes to address them? What 
might be the implications of developing screening when only probabilistic indicators, 
which are derived from a small sector (white males) of the general population, are 
available? Will the identification of ‘brain signatures’ end the debate about social versus 
biological causes of mental illness? 
6.2.2 Scenario 5: The Award Ceremony 
The highly successful Medical Informatics Platform has been refunded by the European 
Union for a second ten years to continue to refine and validate the various disease 
signatures that have come into the public domain and routine clinical use through the 
combined efforts of HBP researchers, pharmaceutical companies, social media 
company, organised patient networks, and bioinformatics experts. But success brings 
its critics and its dilemmas. 
‘It was Saturday afternoon, August 8, 2026. Eugénie was getting dressed for the dinner and 
award ceremony later that evening. She would be receiving a special award for ‘Social 
Media and Health.’ It was her idea that had moved the work of the HBP in identifying brain 
signatures to a new level: the Project had run into trouble because although hospital 
records had enabled brain signatures to be identified, their precision was limited because 
of inadequate lifestyle information; hospitals and clinicians were either unable or unwilling 
to trace back to patients to supplement what data was on the electronic data records.  
Eugénie had had the great idea of developing a social media company that brought 
together Facebook participants to share their data with the Human Brain Project, but this 
was alongside her real success, which was to help negotiate the contracts that would 
enable the HBP to gain access to a massive amount of data from outside the EU which 
would ‘power up’ the data set and help refine the disease signatures so that they were 
precise enough for individual clinical use. As data officer, she also had to handle some 
sensitive media work.  
This past week, Eugénie helped the HBP to distance itself from the legal system in Hungary 
that which had just accepted a brain disease signature as evidence in a criminal 
prosecution. But the most exciting thing was that she was being offered a position on a 
company board! This was a giant leap forward in her career. Facebook was collaborating 
with one of the big pharmaceutical companies in Germany, and as part of this there would 
be a small research company, Pharmakon Sociale, that would serve as the intermediary. 
She was recommended to be on the new Board of Directors as a result of her data sharing 
work. This was a great opportunity for Facebook to monetize their information assets.  
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In the elevator, Eugénie checked her voicemail. Her secretary had called to tell her that a 
political columnist had written an article about the legacy of the HBP Medical Informatics 
Platform in Le Monde. While the journalist grudgingly acknowledged the significance of the 
diagnostic technology that the HBP had helped develop, he focussed more on the conflicts 
around the commercialisation of the technology and the links of the researchers with 
private corporations, on unresolved issues of patient’s rights, and on the dubious ethical 
status of the collaboration with China. Eugénie was named personally in the column as 
someone who had benefited financially from her involvement and hence might have had 
conflicts of interest. “Well, I suppose,” thought Eugénie, “she might as well get used to 
this type of thing. It was just part of being successful.”’ 
This scenario presumes that limited success in establishing identifiable disease signatures 
drives the need for more data and for more refined information to make the disease 
signatures less probabilistic and more precise and useable in clinical work with 
individuals. It considers some of the ways in which this search for more and better 
information might proceed and some of the costs. And it addresses some of the key issues 
concerning the pathways to translation via alliances with commercial companies who can 
take the research from the lab into the clinic. It also raises the possibility that disease 
signatures might be used in the criminal courts in determining culpability (comparable to 
the disputes in the USA about the use of genetic evidence and brain scans in criminal 
trials). 
6.2.3 Scenario 6: Beyond the Brain 
It is five years after the Human Brain Project formally ended, having accomplished 
some minor advances in neuroscience and neuromorphic chip design. However, 
although various disease signatures have been proposed, validation testing and further 
research shows examples of healthy persons with the same brain signature as those 
with clear manifestations of the disease in the clinical setting. What would be the 
implications of this apparent inability to extrapolate from brain signatures to the 
experience of disease? More data seems to be the solution, but how can the rich 
qualitative environmental and experiential data that seems pertinent be made 
compatible with the advanced techniques of data mining required to identify brain 
signatures? 
‘Today is Tuesday May 8, 2029. It is Indira’s second day in the field and she found this 
summer job exciting. She would be driving all over Scandinavia and North Western 
Germany this summer interviewing families about the diet and exercise habits of their 
deceased loved one.  
The Finnish neuroscientist who had hired Indira felt that felt that if only she had additional 
data she might be a step closer to solving the riddle about why the hypothesised disease 
signatures that had been identified in the Human Brain Project, and had been the subject 
of dozens of research papers, only correlated with the onset or severity of 
neurodegeneration in some cases but not others. She had got the idea of ‘verbal autopsies’ 
from public health work in India where many people die in rural communities outside of 
the medical system. The census often uses information provided by surviving relatives in 
the household to give the cause of death.  
The researcher for whom Indira was working had read about this Indian strategy, and 
thought that it could be adapted to provide much more information about those who lived 
with, and died from neurodegenerative diseases. So she was visiting their homes and 
conducting a survey to collect information about the deceased – about their exercise and 
diet, amount of social interaction, employment and work stress, habits of reading or 
watching television; she had even included a question about how often they listened to 





Report on future medicine_Website version Dissemination: PU  26-Jun-2015 Page 43 of 65 
 
music and of what type was the music. And she was also gathering information about the 
kinds of treatment that people had sought, much of it outside the official medical system – 
she found that people experiencing disturbing symptoms of loss of memory used everything 
from herbal remedies to prayer or meditation, and often reported real improvements.  
Although she was not a neuroscientist, Indira had trained in psychology for her 
undergraduate degree, and had developed considerable skills in quantitative statistics. 
What she could not quite understand was how the stories that she was being told by the 
surviving relatives about the lives and habits of their loved ones, and the range of non-
medical treatments that they had used, could be turned into the kinds of data that might 
be used in the quantitative analyses required by neuroscientists. It all seemed so woolly, 
so dependent on beliefs, customs, and the peculiarities of individual lives. Indira wanted 
to apply to graduate school and continue her education in the sciences, and now thought 
she would specialise in neuroscience – surely she would be able to learn how the experts 
managed to turn all these individual experiences, that seemed so real and important if one 
really wanted to understand the progress of the disease, into data.’ 
This scenario considers the possibility that the disease signature identification task set by 
the Medical Informatics Platform may prove too complex to resolve within the very short 
funding cycle of the HBP. However the scenario is optimistic in that it suggests that the 
The HBP has built the Project in such a way that the medical research community and 
young people still feel inspired to take up the challenge. What kind of data collection 
standards could be comprehensive yet flexible to the diverse social and geographic 
situations from which it will be collected? What are the research investment choices that 
the HBP can make that will benefit the medical neuroscience community even after the 
HBP has ended? How might the HBP legacy relate to public health strategies in the regions 
of the world where individuals widely make use of treatments outside the formal medical 
system? 
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7. Annex 2: The Medical Informatics Platform 
We reproduce here some further technical details of the MIP as the Platform has been 
developed in dialogue with the work of the Foresight Lab. 
The HBP Medical Informatics Platform (SP8) will federate large volumes of anonymised 
data (genetic data, imaging data, and other clinical data) originally generated for clinical 
purposes, and make it available to the research community. Procedures for anonymisation 
are described below. Partnering Projects will mine these data for biological signatures of 
disease, which if found, could provide important insights into disease mechanisms, 
contributing to the development of new diagnostic tools and new treatments. The Project 
will encourage community efforts to use Platform data and tools for studies of a broad 
range of brain disorders. Below we discuss the implications of this approach. 
Compliance with European and National Data Protection Law. At the time of writing, 
data protection in EU member states is regulated by EU directive 95/46/EC and by derived 
national legislation. Negotiations for a new Data Protection Regulation are now at an 
advanced stage. Given, however, the draft regulation has yet to be finalised, the 
discussion here will be limited to existing law. 
For the purposes of data protection law, health-related data pertaining to a data subject is 
personal data, and can only be gathered legally under strict conditions, for a legitimate 
purpose. In particular, Recital 33 of the data protection directive provides that “data 
should not be processed unless the data subject gives his explicit consent”2, However, 
Recital 26 states, “the principles of protection shall not apply to data rendered anonymous 
in such a way that the data subject is no longer identifiable.”  
Architectural considerations. In the architecture adopted by the HBP Medical Informatics 
Platform (SP8), all data referring to human subjects is held in local data repositories 
managed by the individual hospitals that contribute data to the Project. There is no 
central repository and no transfer of raw data outside the hospital perimeter. Thus, the 
raw data are protected by the same technical infrastructure and technical measures and 
receives the same legal protection provided to all patient data. This implies that any 
attempt to re-identify patient data would constitute a criminal offense. Access to raw data 
is restricted to authorised personnel. Access is protected by passwords, and additional 
physical protection measures (e.g. use of smart cards), in line with the policies adopted by 
individual hospitals. Servers re protected using the same measures used to protect other 
hospital information systems containing patient data.  
De-identification (anonymisation) of data. Given the recitals of the data protection 
directive, the applicability of Data Protection legislation depends on whether or not the 
data stored in the Medical Informatics Platform can be treated as anonymous data. 
De-identification or anonymisation of data is the process whereby personal data are 
processed with the aim of preventing identification of the data subject. Several 
anonymisation techniques may be envisaged, (and) there is no prescriptive standard in EU 
legislation. Relevant standards and regulations include ISO 29100:2011, and the US HIPAA 
regulation. 
                                            
2 Note the ethical requirement that data subjects should give informed consent for the use of their 
data depend not just on data protection law but also on general principles of medical ethics, as laid 
down in the Helsinki Convention, and on explicit requirements of European and national law. 
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In its Opinion 05/2014 on anonymisation techniques, the EU “Data Protection Working 
Party” examines the robustness of a broad range of anonymisation techniques. The 
Working Party concludes that “anonymisation techniques can provide privacy guarantees 
and may be used to generate efficient anonymisation processes, but only if their 
application is engineered appropriately (…) The optimal solution should be decided on a 
case-by-case basis, possibly by using a combination of different techniques, while taking 
into account the practical recommendations developed in this Opinion.” In the light of 
these recommendations, SP8 has adopted a strategy of “defence in depth” which combines 
different technical and organisational measures. In line with the findings of the Working 
Group, SP8 recognises that anonymity and anonymisation are lively fields of research and 
will update its protection measures as the field progresses. 
Local HBP data repositories contain only anonymised data. Thus, even an HBP user with 
system administrator rights cannot access individual patient records. The data repositories 
are populated using a pipeline that extracts data from hospital medical records, and 
applies filters to remove information that could allow the identification of a patient. The 
procedure includes removal of identifiers and pseudo-identifiers that could allow the re-
identification of patients, as specified by the US HIPAA regulation. It also provides for 
addition of noise to some kinds of clinical data to prevent identification of patients. In 
particular, brain-imaging data are “defaced” (i.e., image parameters are altered to 
prevent reconstruction of a patient’s face). 
No end-user access to raw data. The HBP MIP will provide hospitals with the software to 
post-process the raw data contained in local data repositories and extract features of 
interest (grey and white-matter volumes, as revealed by medical imaging). The post-
processing software is controlled and run by the hospitals. End-users of the Platform will 
be able to query the feature data but not the raw data. De-identified raw data (e.g. 
imaging data) will be conserved in local repositories for use by HBP researchers involved in 
the development of new feature extraction algorithms. Access to the data will be 
restricted to researchers authorised by individual hospital data controllers. 
k-anonymity. The Medical Informatics Platform will use the technique of k-anonymity. The 
Platform will provide end-users with descriptive statistics for particular features (or 
correlations among them) in a set of records matching a query, only when the number of 
records in the set is greater than a threshold-value. If only one or a small number of 
records, satisfy a query, the Platform will not respond to the query. Work is in progress to 
extend this approach to genetic data. The software will include filters that block 
suspicious queries. 
Audit trail. With the protective measures in place it would be virtually possible for an 
attacker to infer data about an individual patient. Nonetheless, the Medical Informatics 
System will maintain an audit trail, recording the origin, time, date and content of 
individual queries and the records used to generate the response. Analysis of these data 
could in principle detect suspicious activity.  
Software. Software implemented in the Medical Informatics Platform, whose development 
has been funded by the HBP, will be released under an open-source license such as BSD. 
The same code will be available for by privacy impact audits (see below). To extract data 
in primary hospital information systems, and remove HIPPA identifiers the HBP will use 
software provided, configured and maintained by Gnubila, a leading supplier of hospital 
software. The software meets HIPAA standards together with additional HBP requirements 
and will allow system administrators to precisely define access rights. The software will 
run on servers managed by hospital staff. The subcontracting company will have no access 
to patient data. 
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Pseudonymity. The policy of some hospitals requires that patients should be able to 
request details of the purposes for which their data have been used. This may make it 
necessary to maintain a table-linking patient codes and identifies. Such a table would be 
held by local hospital data controllers and would not be accessible to HBP staff or to users 
of the HBP platform. Given that researchers using the HBP platform will not have access to 
data for individual patients, they would not be able to use the code to trace individual 
patients. Nonetheless, hospitals that adopted such policies would not be able to treat the 
data as anonymous, and would thus be subject to data protection law. Discussions are in 
progress with hospital administrations to find a suitable solution before the platform 
comes on line. 
Organisational measures and legal responsibility. For the purposes of data protection 
legislation, the data controllers for anonymised patient data held in local hospital 
repositories will be the data controllers in individual hospitals. The data controller for the 
overall Platform and for metadata and provenance files will be the partner responsible for 
the Platform.  
The Medical Informatics Platform is evaluating additional procedural safeguards, regarded 
as best practice for large databanks of medical data 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744675/). An initial set of safeguards 
will be in place before the Platform comes online in Project Month 30. They will include 
the creation of a Data Governance Committee responsible for ensuring that the acquisition 
of data by the HBP Medical Informatics Platform and the use of the data by users of the 
Platform comply with relevant law, regulation and professional standards. The committee 
will include representatives of different stakeholders including data providers, and 
members of local IRB.  
Privacy impact assessment. A recent stakeholder forum managed by WP12.3 and SP8 
suggested that anonymisation techniques should be subjected to a Privacy Impact 
Assessment by an independent third party. SP8 agrees and is discussing how the 
recommendation should be implemented. Results will be reported in the next review. 
Technical measures to enforce anonymisation. Metadata associated with clinical records 
stored in local hospital data repositories will routinely include details of the hospital 
archive from which the data was taken, the form of consent, the location of consent 
documents, measures to de-identify the data, and relevant data use agreements and plans 
(see below). The HBP provenance tracking system will make it possible to analyse these 
data and to retroactively exclude data that does not meet emerging ethical standards. 
Informed Consent. Informed consent for use of patient data for scientific purposes is a 
requirement, not just of European and national data protection law, but also of general 
medical ethics, as codified in the Helsinki convention, and in European and national 
legislation on human experimentation. 
There are differences among European policy-makers concerning the appropriate trade-off 
between the social benefits to be derived by exploiting patient records for research, and 
patients’ right to control their personal data. These differences are reflected in 
differences in national law and jurisprudence. These issues were recently exposed in the 
controversy about the Care.data programme in the UK 
(http://www.england.nhs.uk/ourwork/tsd/care-data/), which has met severe obstacles, 
due to lack of adequate consultation with the citizens whose data was to be shared and 
inadequate procedures for patients to 'opt out.’ However, Care data proposed to use 
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individual data. In the Ramp-Up Phase the HBP will use only aggregate data 3  (see 
discussion of anonymity above) 
Legal and regulatory differences are reflected in the different policies adopted by 
different European countries and in the debate on Europe’s future Data Protection 
Regulation, where one of the themes is the use of anonymous health data for health 
research. SP10 will advise the BoD and the ExCo on the on-going debate. Currently, the use 
of patient data for research is regulated by national and local laws and regulations, as 
interpreted by local IRBs.  
A key issue is the secondary use of anonymised historical data, collected for purposes of 
diagnosis or treatment, and during clinical trials. Given that, in many cases patients have 
not consented to the use of their data for research, this raises ethical issues. The 
organisations providing data to the HBP Medical Informatics Platform will apply applicable 
national regulations, deontological standards and accepted procedures, whose details will 
vary by country. At the time of writing, we have full information only for the CHUV, the 
Swiss hospital that leads SP8. Similar information will be collected for all participating 
hospitals and made available to the EC, before the data are deposited in the Platform 
(which will only start full operation in Project Month 30). No data will be collected from 
any institution without a data sharing agreement, in which the contributing institution 
certifies the informed consent procedures applying to the data and their approval by the 
relevant IRB. The metadata describing data sets and data records will always specify the 
form of consent given by the patient. 
A second issue is how to reform models of informed consent for future patients. Many 
ethicists and clinicians would agree that data cannot be used unless patients have given 
their consent. However, there is growing recognition that it is not always possible to 
enumerate the different ways in which future researchers may wish to use specific classes 
of clinical data. This has led to suggestions for forms of “open consent” that cover a broad 
range of possible uses. Obviously the use of such consent procedures should itself be 
subject to ethical review by the relevant IRB. Clinicians and ethicists working in the HBP 
are participating in public and academic debate around this issue. In the meantime, they 
will work with local hospital administrations and ethics committees to develop informed 
consent procedures that provide meaningful protection to patients, while simultaneously 
enabling effective research. 
Requests for Ethical Approval. No clinical data will be made available through the Medical 
Informatics Platform without the approval of the hospitals or other organisations holding 
the data. These organisations will be responsible for requesting ethical approval (where 
required) from the relevant Independent Review Boards. In the early stages, it is expected 
that the majority of these organisations will be located in Switzerland. At later stages, the 
Project will involve hospitals all over Europe. Staff in the HBP Ethics and Society 
Programme (SP10) and staff from the Medical Informatics SP will assist hospitals in 
formulating their applications and in providing any information IRBs may require. 
                                            
3 In a late phase of the Project, the HBP plans to develop services for personalized medicine. These 
will probably be managed by a new legal entity set up for this purpose. Individual data used for such 
services will be covered by the confidentiality requirements of the doctor –patient relationship, and 
will not be made available to researchers. Informed consent procedures for patients contributing 
data to the service will conform to the legislation and ethical regulations in force at the time (late 
in the Project) when the service comes into operation. 





Report on future medicine_Website version Dissemination: PU  26-Jun-2015 Page 48 of 65 
 
The goal of the Project is that all necessary applications for ethical approval should be 
completed not later than the end of Month 24, and that all requests should be approved 
not later than Month 30. 
  





Report on future medicine_Website version Dissemination: PU  26-Jun-2015 Page 49 of 65 
 
8. Annex 3: Collaboration with the Danish Board of 
Technology Foundation  
8.1 A Collaborative Approach 
The Foresight Lab and the Danish Board of Technology Foundation (DBT) co-organised two 
webinars on 7 May 2014. One webinar focused on data federation and data protection, the 
other disease signatures and personalised medicine. A range of stakeholders considered 
the social and ethical issues raised by the plans of the MIP to federate clinical data from 
across Europe and mine them with the aim to isolate biological signatures of brain 
diseases. Details about the webinars and participant stakeholders are in Annex 8.2. 
To build on the webinars and explore more thoroughly the challenges they had helped to 
identify, the Foresight Lab developed background material based on these challenges as 
well as on preparatory meetings and interviews with MIP members, MIP presentations and 
reports, and both scholarly and grey literature review. We elaborated two series of three 
narrative and fictional short scenarios, also called vignettes, one for each of the main 
topics: Data federation and privacy, and disease signatures. 
The vignettes served as a basis for discussion in a follow-up stakeholder seminar that we 
organised again in collaboration with the Danish Board of Technology Foundation (DBT), 
which took place in Copenhagen on 8 and 9 October 2014. The DBTF planned it according 
to the ‘a dinner and a day’ approach to scenario-making, a concept originally pioneered by 
Shell. The event involved diverse external stakeholders as well as collaborators of the MIP. 
Participants were split in three working groups, each with a facilitator and a rapporteur. 
One group in particular focused exclusively on the topic of data federation and privacy. 
The discussions initiated from the vignettes both refined and expanded the range of issues 
that had been identified, and zoomed in on a number of short term challenges that were 
debated in greater depth. 
The teams who collaborated in the organisation of the webinars and seminar have been 
using their results in various outputs. Besides our report on Future Medicine, the DBTF has 
published a policy brief on privacy and informed consent in the Human Brain Project. The 
results also feed into a European citizens’ convention organised by the DBTF and a 
citizens’ online deliberation forum organised by the Institute Pasteur (IP), Paris Institute. 
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8.2 Webinars 
We reproduce below the programmes and background material prepared and circulated by 
the Danish Board of Technology Foundation prior to the webinars. 
8.2.1 Webinar on data federation and protection: social, ethical and legal issues - 
Programme and Background material 
8.2.1.1 Aims of the webinars 
The webinars are a forum where Human Brain Project (HBP) stakeholders and relevant 
experts can have a constructive dialogue with regard to ideas, considerations and concerns 
arising from HBP research, discoveries and technologies. In particular, this webinar will 
aim at strengthening the HBP researchers’ understanding of the broader social, political, 
ethical, legal implications of their work.  
The objective of this webinar will be to discuss the ethical and social issues that may arise 
from the federation of data, data protection and their use to personalise medicine. This 
may also involve a wider consideration of the social implications related to the future of 
medicine.  
During the webinar there will be four presentations, each followed by questions raised by a 
HBP panel (see timetable page 3).  
8.2.1.2 The speakers  
Dennis-Kenji Kipker is a member of the European Academy for Freedom of Information 
and Data Protection (EAID) and of the German Association for Law and Informatics (DGRI). 
He studied from 2006-2011 law at the University of Bremen with a focus on information 
and medical law, promoted by the German National Academic Foundation. Since 2011, he 
works as a research associate and a member of the universities Ethics Commission at the 
Institute for Information, Health and Medical Law in Bremen with a research emphasis on 
medical data protection law as well as police and intelligence agency law. After several 
publications and teaching assignments as a guest lecturer in Germany, Austria and Poland, 
he plans to finish his dissertation in autumn 2014. For more information: 
http://www.jura.uni-bremen.de/personen/dennis-kenji-kipker/  
Dirk Lanzerath is General Secretary of the European Network of Research Ethics 
Committees (EUREC). He holds a doctoral degree in Philosophy (Dr. phil.) at the University 
of Bonn (1998); Habilitation (Philosophy) in Bonn (2013). He is Senior Research Assistant at 
the Philosophy Department (LFB II) of the University of Bonn (1993-1994); Senior Research 
Assistant at the Institute of Science and Ethics in Bonn (1994-1998); Head of the Research 
Department at the German Reference Centre for Ethics in the Life Sciences (DRZE), 
University of Bonn (1998-2002); since 2002 Executive Manager of the DRZE, University of 
Bonn. Since 1995 Lecturer of Philosophy at the University of Bonn; since 1996 Guest 
Lecturer at Loyola Marymount University, Los Angeles, Ca. He is also Member of the 
European Faculty of the Bioethics Program at the Graduate College of Union University 
Schenectady and Albany Medical College, NY, the Editorial Board of the Journal "Research 
Ethics Review,” the Central Ethics Committee at the German Physician Association and the 
Review Board of UNESCOS's Global Ethics Observatory Database (GEObs).  
Paul Quinn is a researcher at the Vrije Universiteit Brussel. He has, in the past few years, 
conducted research on legal issues that surround legal issues in telemedicine and medicine 
in general focusing on patients’ rights and privacy. He has worked on a number of 
European FP7 projects concerning such issues and has published his findings. Originally 
from the UK, Paul originally obtained a BSc in Biochemistry before converting to Law and 
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training as a Barrister. For more information: 
http://www.vub.ac.be/LSTS/members/quinn/   
Caspar Bowden is an independent advocate for information privacy rights, and public 
understanding of privacy research in computer science. He is a specialist in EU Data 
Protection, European and US surveillance law, PET research, identity management, and 
information ethics. He is author of 2013 EU Parliament inquiry briefing on the US FISA law, 
and co-authored the 2012 Note on privacy and Cloud computing (which anticipated the 
infringements to EU data sovereignty disclosed by Edward Snowden). For nine years he was 
Chief Privacy Adviser for Microsoft for forty countries, and previously co-founded and was 
first director of the Foundation for Information Policy Research (www.fipr.org). He was an 
expert adviser for UK Parliamentary legislation, and co-organised six public conferences on 
encryption, data retention, and interception policy. He has previous careers in financial 
engineering and risk management, and software engineering (systems, 3D games, applied 
cryptography), including work with Goldman Sachs, Microsoft Consulting Services, Acorn, 
Research Machines, and IBM. He founded the Award for Outstanding Research in Privacy 
Enhancing Technologies, is a fellow of the British Computer Society, and a member of the 
advisory bodies of several civil society associations.  
8.2.1.3 The HBP panel 
 Medical Informatics Platform: Thomas Heinis (Postdoctoral research Fellow in the Data-
Intensive Applications and Systems Lab at the École Polytechnique Fédérale de 
Lausanne) 
 Society and Ethics Program: Nikolas Rose (Professor of Sociology and Head of the 
Department of Social Science, Health and Medicine at King’s College London) 
8.2.1.4 The audience  
 HBP members 
 Researchers from the Medical Informatics Platform and the Society and Ethics Program 
 Others from HBP: Ethics committees members, industry relations, communication team 
 Stakeholders 
 Researchers and experts coming from different backgrounds, such as bioethics, 
neuroscience, social science, cognitive science, the private sector, etc. 
8.2.1.5 Webinar timetable 
Time (CET) Presentations 
10:00 – 10:05 Introduction by Chairman 
10:05 – 10:20 Dennis-Kenji Kipker 
10:20 – 10:30 Q&As by HBP panel 
10:30 – 10:45 Dirk Lanzerath 
10:45 – 10:55 Q&As by HBP panel 
10:55 – 11.10 Paul Quinn 
11:10 – 11:20 Q&As by HBP panel 
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11:20 – 11:35 Caspar Bowden 
11:35 – 11:45 Q&As by HBP panel 
11:45 – 12:00 Closing comments by HBP panel 
8.2.1.6 Background 
This webinar is the first stakeholder activity arranged by the Danish Board of Technology in 
collaboration with King’s College London - both part of Subproject 12 , “the Ethics and 
Society” Program of HBP (https://www.humanbrainproject.eu/ethics-and-society). The 
task of the Danish Board of Technology in HBP is to promote engagement of outside 
experts and stakeholders and create dialog with HBP researchers.  
In the Human Brain Project (HBP) it is the Subproject 8 that will deliver the Medical 
Informatics Platform (MIP), where they will transform medical records into research data, 
extract knowledge and build models of brain diseases. Inference from these models will 
forward the field of medicine from descriptive symptomatology toward diagnostic, 
predictive and prescriptive personalised medicine.  
Thus, it is the work done in their Subproject which is at focus in this twofold webinar on 1) 
data federation and protection and 2) disease signatures and personalised medicine.  
In the following we will provide you with descriptions of the goals and methods for 
obtaining those that have been provided by the Subproject 8. The methods described 
below will focus on data federation and protection, as it is the theme of this webinar.  
8.2.1.7 The overall goal of the Medical Informatics Subproject in HBP 
The first goal of the Medical Informatics Subproject is to federate hospital and other 
clinical data on all brain diseases across multiple levels of biology for data mining and rule-
based cluster analysis. The ultimate goal is to derive unique objective biological signatures 
of brain disease, which will be used to improve diagnoses, establish more accurate 
prognoses, and develop new drug discovery pathways. 
Clinical data, tools for data mining, and rule-based clustering will be provided through a 
Medical Informatics Platform. The Medical Informatics Platform will become a service for 
a) clinicians for objective diagnoses and treatment of brain disease, b) neuroscientists to 
apply, test and input new models and methods, and c) pharmaceutical and biotech 
companies for disease target discovery. Unique biological signatures of a disease will also 
serve as prescriptions to configure brain models of disease for simulation-based predictions 
across inaccessible levels of biology, studying the causal chain of events in brain diseases, 
and performing drug simulations.  
The MIP will provide end-to-end solutions from the data to advanced analytical tools. 
Researchers will be able to investigate questions requiring data correlations, distributions 
and interactions in the context of disease processes and epidemiological factors. Using 
analytical tools provided, researchers will be able to decipher the relationship between 
biological variables and clinical phenotypes. Simultaneously and continuously, as data 
accrue with time and recruitment of new hospitals and data generators, data mining tools 
will explore all the data to detect recurrent patterns identifying in this way biological 
signatures of disease. The biological signatures of disease will form the basis for a new 
disease spac e that neuroscientists and clinicians can explore.  
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8.2.1.8 Methods for data federation and protection 
The MIP will federate data from multiple sources to allow researchers to interrogate them 
in a unified, transparent and efficient way. The privacy of data will be strictly maintained 
through rigorous anonymisation and access rules. 
The MIP will build on public and research databases, and hospital data, federated by novel 
data management and query techniques. This federation software and hardware will allow 
researchers to query and analyse a very large volume of data without moving them from 
local servers and without compromising data privacy.  
The anonymisation of the local data uses a two-pronged approach to accomplish its task:  
 Personal identifiers shall be removed when exporting data from hospital information 
systems, i.e. even before the MIP accesses the data for the first time 
The MIP shall only allow aggregate queries to run and shall filter all results (ensuring they 
do not contain personal patient information) before returning them to users of the 
Platform. 
Hospital data are often stored locally in disparate sources, of various technologies and 
with different schemata. Each participating hospital will be requested to build a local data 
warehouse. This will allow data to be accessed and interrogated by the MIP in the most 
efficient and secure manner, fully maintaining its accuracy, consistency and privacy. An 
Extract/Transform/Load (ETL) process will be used for populating local data warehouses 
(called Local Data Store Mirrors). 
All query results coming from a Local Data Store Mirror are filtered for any personal 
identifiers left (e.g. headers of imaging data) when they leave the Local Data Store Mirror 
and enter the Data Federation system. Data security and privacy follow principles 
established by data governance bodies, which include SP8 team and local data providers. 
HBP’s in situ query technology will make it possible to query data stored on local hospital 
servers without moving it to a central location. When implementing the technology, the 
HBP will adopt a pragmatic strategy that guarantees respect for differing local regulations, 
the privacy policies of hospitals and any additional restrictions on use requested by 
individual patients (e.g. restrictions on the use of specific categories of data). To meet 
this need, they will develop novel configurable security mechanisms both at the Platform 
level and the general data release level. At the Platform level, they will develop novel 
access control techniques, to be deployed on local servers, giving data owners (hospitals, 
research institutions etc.) fine-grained control over the configuration of security 
permissions (general policies, policies for individual patients, policies for individual items 
of data) and ensuring that authorised personnel maintain the ability to access individual 
data in an emergency (e.g. when a researcher finds an undetected tumour in neuroimaging 
data). They will also develop additional statistical tools that make it possible to quantify 
how much information has been disclosed to which researchers and in what form.  
8.2.1.9 Data 
The data provided by hospitals include raw data, such as imaging data (MRI, PET), CSV/XLS 
files, raw text, output of proprietary medical systems, as well as relational databases. The 
data traverse a series of sub-processes. They are anonymised, normalised and integrated. 
Finally, the data and the information extracted from them are released (i.e., made 
available for in-situ query) as Variables associated with Provenance descriptors.  
8.2.1.10 Variables 
Variables are metadata that provide scientific descriptions of data. Variables are extracted 
by a mixture of number crunching, image processing and text mining, and are mapped to a 
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common standard. Variable extraction data processing happens at the Data Store Mirror 
level in each data provider site, locally in most cases.  
Below are the Variable descriptions, along five dimensions:  
 Scale – genetic, molecular, cellular, circuits, systems.  
 Time – data acquisition at single point/multiple points per subject.  
 Space – centred on the brain (based on brain regions).  
 Pathology – clinical labels of brain pathology.  
 Demographics – age, gender.  
8.2.1.11 Provenance 
For each of the Variables the Provenance describes precisely the materials and methods 
(exact algorithms and their versions) used to create them:  
 Materials: brain imaging – magnetic resonance imaging/computer tomography/PET, 
neurophysiology, etc.  
 Methods: voxel-based morphometry – volume, surface-based morphometry – cortical 
folding, power spectra, SI units for biochemical assays, etc.  
8.2.1.12 Ontologies 
Ontologies are controlled vocabularies describing the Variables and relations among them 
with a meaningful grammar in the specific domain of interest (clinical phenotype, medical 
terms, brain regions, genes and proteins). In the first instance, we will use established 
ontologies for each domain, which will be updated as required. Examples of Ontologies: 
ICD-10/9 disease classification from the World Health Organisation adopted by hospitals, 
OMIM, DiseasesDB, eMedicine.  
8.2.1.13 Data Integration and Federation 
Data Integration is the process of merging data from different sources. Data Federation is a 
type of Data Integration. This is a process and virtual database that allows queries to 
heterogeneous and fragmented databases with a “no copy” and “no move” policy in 
relation to original source data. The virtual database contains only the Variables and the 
Provenance describing the original data in the local databases at each site in the network 
of MIP-associated infrastructures. 
8.2.1.14 Ethical and regulatory issues 
Subproject 8’s work will lead to new techniques for the early diagnosis of neurological and 
psychiatric disease, and for personalised treatment (predictions of response to treatment; 
reduction of adverse drug reactions etc.), which the Medical Informatics Platform will 
make available to the research community and clinicians. The processes of data federation 
and the new techniques of data mining for disease signatures to guide clinical 
interventions raise immediate and longer-term legal, ethical and social issues. Issues of 
immediate concern include questions related to the use of anonymised data, data 
protection and informed consent. Many other questions arise from the wish to personalise 
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8.2.2 Webinar on disease signatures and personalised medicine: social, ethical and 
legal issues - Programme and background material 
8.2.2.1 Aims of the webinars 
The webinars are a forum where HBP stakeholders and relevant experts can have a 
constructive dialogue on ideas, considerations and concerns arising from HBP research, and 
technologies.  
The objective of this webinar is to discuss the ethical and social issues that may arise from 
the identification of disease signatures and their use to personalise medicine. This may 
also involve a wider consideration of the social implications related to the future of 
medicine. This webinar will strengthen HBP researchers’ understanding of the broader 
social, political, ethical, legal implications of their work. 
During the webinar there will be four presentations, each followed by questions raised by a 
HBP panel (see 8.2.1.5).  
8.2.2.2 The speakers  
Emilio Mordini is a Psychiatrist and Philosopher. He currently chairs Responsible 
Technology, a French consultancy devoted to responsible research and innovation. He has 
been formerly trained as a psychoanalyst and taught bioethics in the Medical School of the 
University “La Sapienza” of Rome (1994-2005). He served as a scientific secretary of the 
Bioethical Commission of the Italian National Research Council (1996-2004), and as a 
director of the Centre for Science, Society and Citizenship (2002-2013). He is a member of 
the management committees of the COST Action IC1106 Integrating Biometrics and 
Forensics for the Digital Age, and the COST Action IC1206 De-identification for privacy 
protection in multimedia content. He serves in a number of scientific and editorial 
committees. He has extensively published in academic peer reviewed publications, and 
edited 14 books. Emilio’ s research interests have focused on the notion of social 
unconscious – which derives from scholars such as Castoriadis, Hopper, Weinberg, and 
Taylor – and applied it to ethical and societal aspects of emerging technology and science. 
Doug Brown is the Director of Research and Development at the Alzheimer’s Society. 
Increasing investment in research is a key goal of the Alzheimer’s Society which aims to 
invest more than £10 million a year in dementia research by 2017, and has committed to 
spending at least £100m over the next decade. The research programme will continue to 
provide a vehicle for funding across the spectrum of dementia research, into the cause, 
cure, care and prevention of dementia, and will focus on translating and implementing 
research findings for ultimate benefit of people affected by dementia. Doug is also a 
Trustee of the Association of Medical Research Charities.  
Barbara Prainsack is Professor of Sociology at the Department of Social Science, Health & 
Medicine at King's College London. Her work addresses the regulatory, social, and ethical 
dimensions of bioscience and biomedicine. Recent publications include: Genetics as Social 
Practice (Ashgate, 2014; ed. with Silke Schicktanz and Gabriele Werner-Felmayer), 
and Solidarity: Reflections on an Emerging Concept in Bioethics (Nuffield Council on 
Bioethics, 2011; with Alena Buyx). From 2011-2013 Barbara led the European Science 




Gregor Wolbring is Associate Professor in Department of Community Health Sciences, 
Stream Community Rehabilitation and Disability Studies, Faculty of Medicine, Calgary, 
Canada. He holds a diploma in Biochemistry at the University of Tübingen and at the 
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University College London, UK. Parallel to his biochemistry work he did policy work around 
disability issues and around emerging technologies. That culminated in a faculty position 
covering these topics in 2008. He has interest in ability governance, Social, ethical, legal, 
economic, cultural and governance issues of new, emerging and converging sciences and 
technologies (S&T), bioethics etc. For more information: 
http://www.crds.org/research/faculty/Gregor_Wolbring2.shtml  
8.2.2.3 The HBP panel (asking questions following each presentation) 
 Medical Informatics Platform: Ferath Kherif (Deputy Director, Laboratoire de 
Recherche en Neuroimagerie, CHUV/UNIL) 
 Society and Ethics Program: Nikolas Rose (Professor of Sociology and Head of the 
Department of Social Science, Health and Medicine at King’s College London) 
8.2.2.4 The audience  
 HBP members 
 Researchers from the Medical Informatics Platform and the Society and Ethics Program 
 Others from HBP: Ethics committee members, industry relations, and the 
communication team 
 Stakeholders 
 Researchers and experts coming from different backgrounds: bioethics, neuroscience, 
social science, cognitive science, and the private sector. 
8.2.2.5 Webinar timetable 
Time (CET) Presentations 
13:00 – 13:05 Introduction by Chairman 
13:05 – 13:20 Emilio Mordini 
13:20 – 13:30 Q&As by HBP panel 
13:30 – 13:45 Doug Brown 
13:45 – 13:55 Q&As by HBP panel 
13:55 – 14.10 Barbara Prainsack 
14:10 – 14:20 Q&As by HBP panel 
14:20 – 14:35 Gregor Wolbring  
14:35 – 14:45 Q&As by HBP panel 
14:45 – 15:00 Closing comments by HBP panel 
8.2.2.6 Background  
This webinar is the first stakeholder activity arranged by the Danish Board of Technology in 
collaboration with King’s College London - both part of Subproject 12, which is the Ethics 
and Society Program of HBP (https://www.humanbrainproject.eu/ethics-and-society). The 
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task of the Danish Board of Technology in HBP is to promote engagement of outside 
experts and stakeholders and create dialog with HBP researchers.  
HBP Subproject 8 will deliver the Medical Informatics Platform (MIP), which will be used to 
transform medical records into research data, extract knowledge and build models of brain 
diseases. Inference from these models will advance the field of medicine from descriptive 
symptomatology toward diagnostic, predictive and prescriptive personalised medicine.  
Thus, SP8’s work is the focus of this twofold webinar on 1) data federation and protection 
and 2) disease signatures and personalised medicine.  
8.2.2.7 The overall goal of the HBP Medical Informatics Subproject  
The first goal of the Medical Informatics Subproject is to federate hospital and other 
clinical data on all brain diseases and across multiple levels of biology for data mining and 
rule-based cluster analysis. These data will be used to derive unique objective biological 
signatures of brain disease, which will in turn be used for diagnosis, more accurate 
prognosis and new types of drug discovery for the development of new medicines. 
Clinical data, tools for data-mining and rule-based clustering will be provided through a 
Medical Informatics Platform. The Medical Informatics Platform will become a service for 
a) clinicians for objective diagnoses and treatment of brain disease; b) neuroscientists to 
apply, test and input new models and methods; and c) pharmaceutical and biotech 
companies for disease target discovery. Unique biological signatures of a disease will also 
serve as prescriptions to configure brain models of disease for simulation-based predictions 
across inaccessible levels of biology, studying the causal chain of events in brain diseases, 
and performing drug simulations.  
The MIP will provide end-to-end solutions from the data to advanced analytical tools. 
Researchers will be able to investigate questions requiring data correlations, distributions 
and interactions in the context of disease processes and epidemiological factors. Using the 
analytical tools provided, researchers will be able to decipher the relationship between 
biological variables and clinical phenotypes. Simultaneously and continuously, as data 
accrue with time and recruitment of new hospitals and data generators, data mining tools 
will explore all the data to detect recurrent patterns identifying in this way biological 
signatures of disease. The biological signatures of disease will form the basis for a new 
disease space that neuroscientists and clinicians can explore.  
8.2.2.8 Methods for disease signatures and personalised medicine 
Machine learning and data mining tools will provide a comprehensive classification of brain 
diseases based on biological signatures, i.e., parameterised combinations of biological 
features and markers. The biological signature of brain diseases will form the basis for a 
new multi-dimensional brain disease space, facilitating scientific investigation and 
permitting personalised medicine. 
To secure anonymisation when MIP release data to contributors of the HBP, the software 
used in the HBP will preserve researchers’ ability to select data based on patients’ 
personal attributes (gender, age, country/region of origin, country/region of residency, 
ethnic origin, clinical diagnosis etc.) while providing mathematical proof that it is 
impossible to identify the presence of a specific individual in a given data set. 
The HBP seeks to provide researchers in medicine and pharmacology with the tools they 
need to accelerate research into the causes, diagnosis and treatment of neurological and 
psychiatric disease. The HBP has four long-term aims: 
1) To identify differential disease signatures from clinical data made available through 
the Medical Informatics Platform (Subproject 8) and to develop new nosological 
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classifications based on predisposing factors and biological dysfunctions rather than 
symptoms and syndromes. 
2) To use biological signatures of disease as a source of insights into disease processes, 
testing specific hypotheses of disease simulation through modelling and simulation. 
3) To use disease models to identify potential drug targets and other possible treatment 
strategies and to predict desirable and adverse effects. 
4) To develop strategies for personalised medicine, allowing the development of 
treatments adapted to the specific condition of individual or specific subgroups of 
sensitive or vulnerable patients. 
8.2.2.9 Biological Signatures of Diseases 
The Biological Signatures of Diseases are deterministic mathematical constructs that aim 
to describe variability both at the phenomenological level (clinical features with symptoms 
and syndromes) and at the biological level (genetic, proteomic, etc.). Biological signatures 
of disease account for the fact that a symptom of brain dysfunction can be due to many 
biological causes (one-to-many symptom mapping) and that a biological cause can present 
with many symptoms (many-to-one symptom mapping). In reality, the situation is often 
one of many mappings between symptoms and biological causes. With advanced computing 
power and data mining, nearly exhaustive searches of a data space can be performed to 
identify sets of rules that describe homogeneous populations, to explain their biological 
data and to predict the pattern of symptoms.  
Biological Signatures of Diseases are the results of a continuous dynamic data mining 
process of clinical data in local data sources. These results are aggregated to generate a 
single multi-modal description of the disease space. 
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Illustration of the biological signature of brain diseases/Continuous data mining process: 
 
Example of how the disease signatures could be used by a clinician in neurology, Beth: 
 Preconditions:  
 The biological signatures of diseases produced by the data mining algorithms are 
available at the MIP Web Portal.  
 The Variables that describe each disease signature cluster have been released and 
are available at the MIP Web Portal.  
 Success scenario: 
 Beth is interested in taking forward personalised diagnostics using the biological 
signatures of the disease.  
 She selects the Biological Signatures of Diseases service and uses the interface to 
classify her own patient by comparing his clinical and biological characteristics with 
the whole range of provided biological signatures of diseases using an optimal 
matching algorithm.  
 She does this by selecting Variables of interest – e.g. demographic data, blood 
cholesterol, neuropsychological scores, genetic burden, etc.  
 She enters values for those Variables.  
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 She retrieves a list of disease signatures ordered according to the best match. The 
distribution of values of the other unselected Variables is also displayed along with 
their uncertainty – e.g. genotype, clinical scores, cardio-vascular risk factors.  
 She also retrieves a 3D brain map with highlighted anatomical regions affected by 
the particular disease corresponding to the optimally matched disease signature. 
She can compare the map with the anatomy pattern of her own patients.  
 Depending on how well the disease signature cluster matches her criteria, Beth can 
add new Variables to determine the stability of her classification in relation to the 
number of criteria or Variables used. 
 She can compare the derived disease signature cluster to conventional clinical 
classification - e.g. ICD-10, DSM V classification.  
 If needed, she can review her patients (data) to verify the derived disease 
signature cluster by similarity and by differences with other patients.  
8.2.2.10 Ethical issues 
Subproject 8’s work will lead to new techniques for the early diagnosis of neurological and 
psychiatric disease, and for personalised treatment (predictions of response to treatment; 
reduction of adverse drug reactions etc.). The Medical Informatics Platform will make 
these tools available to the research community, and ultimately, to clinicians. The 
processes of data federation and the new techniques of data mining for disease signatures 
to guide clinical interventions raise immediate and longer-term legal, ethical and social 
issues. Issues of immediate concern include questions related to the use of anonymised 
data, data protection and informed consent. Many other questions arise from the wish to 
personalise diagnosis and treatment in neurological and psychiatric diseases. Issues of 
immediate concern include questions related to the use of anonymised data. Equally 
important are longer-term issues of therapeutic equity. 
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